# 2025年11月25日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 疫苗接种对预防长新冠影响的系统性综述和荟萃分析。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285857](https://pubmed.ncbi.nlm.nih.gov/41285857)
**期刊：** Nature communications
**PMID：** 41285857
**DOI：** 10.1038/s41467-025-65302-0

### 第一部分 原文与翻译

**英文原标题：** A systematic review and meta-analysis of the impact of vaccination on prevention of long COVID.

**英文摘要原文：**
Long COVID affects millions worldwide and its prevention is a critical public health strategy. While prior analyses show primary vaccination prevents long COVID in subsequent infections, the effect of booster vaccination on long COVID after Omicron infections is unclear. This systematic review identifies 31 observational studies, of which 11 are suitable for pairwise meta-analyses. The pooled odds ratio (OR) of long COVID in those vaccinated (any dose) versus unvaccinated is 0.77 (95% confidence interval [CI] 0.70-0.85; p < 0.0001; 10 studies). ORs were also lower for primary course vaccination versus unvaccinated (OR 0.81; 95% CI 0.79-0.83; p < 0.0001; 3 studies), booster vaccination versus unvaccinated (OR 0.74; 95% CI 0.63-0.86; p = 0.0001; 4 studies), and booster vaccination versus primary course vaccination (OR 77; 95% CI 0.65-0.92; p = 0.0044; 3 studies). These findings indicate that booster vaccination can provide additional protection against long COVID, highlighting the importance of seasonal vaccination against new SARS-CoV-2 variants. They should, however, be interpreted cautiously, given the small number of studies and the low quality of evidence.

**中文摘要译文：**
长新冠（Long COVID）影响全球数百万人，其预防是一项至关重要的公共卫生策略。尽管既往分析表明，基础免疫接种可预防后续感染中的长新冠，但加强针接种对奥密克戎（Omicron）感染后长新冠的影响尚不明确。本系统性综述识别了31项观察性研究，其中11项适用于配对荟萃分析。在接种疫苗者（任何剂量）与未接种疫苗者中，长新冠的合并比值比（OR）为0.77（95%置信区间[CI] 0.70-0.85；p < 0.0001；10项研究）。与未接种疫苗者相比，完成基础免疫接种者的OR同样较低（OR 0.81；95% CI 0.79-0.83；p < 0.0001；3项研究）；与未接种疫苗者相比，接种加强针者的OR也更低（OR 0.74；95% CI 0.63-0.86；p = 0.0001；4项研究）；与完成基础免疫者相比，接种加强针者的OR也更低（OR 0.77；95% CI 0.65-0.92；p = 0.0044；3项研究）。这些发现表明，加强针接种可以为预防长新冠提供额外保护，凸显了针对新出现的SARS-CoV-2变异株进行季节性疫苗接种的重要性。然而，鉴于纳入的研究数量较少且证据质量较低，对这些结果应谨慎解读。

### 第二部分 AI 大师评价

本研究通过系统性综述与荟萃分析，旨在量化新冠疫苗接种（特别是加强针）对预防长新冠的保护效果。研究关键发现表明，无论是基础免疫还是加强针接种，均能显著降低长新冠的发生风险，且加强针能提供额外的保护。该研究为后疫情时代，尤其是在奥密克戎变异株流行背景下，持续推进疫苗接种（如季节性接种）的公共卫生策略提供了重要的数据支持，但作者也审慎地指出了研究基于的证据数量有限且质量不高，结论需谨慎解读。

---

## 2. 跨哺乳动物的抗癌免疫监视

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285854](https://pubmed.ncbi.nlm.nih.gov/41285854)
**期刊：** Nature communications
**PMID：** 41285854
**DOI：** 10.1038/s41467-025-65286-x

### 第一部分 原文与翻译

**英文原标题：** Immunological surveillance against cancer across mammals.

**英文摘要原文：**
Contrary to expectations based on their higher cell numbers, larger and longer-lived species do not face dramatically increased risk of cancer. This strongly suggests that evolution has fashioned natural cancer resistance mechanisms, yet our knowledge remains limited on what these mechanisms might be. The cancer immunological surveillance hypothesis, proposed by Burnet and Thomas in the 1950s, highlights immunity as a key factor determining species-specific cancer resistance. Here we address the original, evolutionary interpretation of this hypothesis by investigating the relationship between cancer mortality risk and markers of efficient antigen presentation. Our results show that the expansion of the MHC class I gene complex, as well as increased selection for diversity at these genes is associated with sharply decreasing cancer mortality risk across mammals. This suggests that the efficient presentation of diverse peptides in somatic cells is important for cancer suppression across mammals, providing pioneering evidence that supports the cancer immunosurveillance hypothesis across species.

**中文摘要译文：**
与基于其更高细胞数量的预期相反，体型更大、寿命更长的物种并未面临显著增加的癌症风险。这有力地表明，进化已塑造了自然的抗癌机制，但我们对这些机制可能是什么的了解仍然有限。由Burnet和Thomas在20世纪50年代提出的癌症免疫监视假说，强调了免疫是决定物种特异性抗癌能力的关键因素。在此，我们通过研究癌症死亡风险与高效抗原呈递标志物之间的关系，来探讨该假说的原始进化论解释。我们的研究结果显示，MHC I类基因复合体的扩增以及这些基因多样性选择的增加，与哺乳动物癌症死亡风险的急剧下降相关。这表明，在体细胞中高效呈递多样化的肽对于抑制哺乳动物的癌症至关重要，为支持跨物种的癌症免疫监视假说提供了开创性证据。

### 第二部分 AI 大师评价

该研究旨在从进化的角度探究哺乳动物抗癌能力的分子基础，特别是检验经典的“癌症免疫监视”假说。通过跨物种比较分析，研究者创新性地将癌症死亡风险与主要组织相容性复合体（MHC）I类基因的扩增及多样性选择关联起来。其核心发现是，更强大和更多样化的MHC I类基因系统与更低的癌症死亡风险显著相关，这为免疫系统在物种长期演化中抑制癌症提供了开创性的证据，对理解癌症的自然防御机制及肿瘤免疫学具有重要价值。

---

## 3. 微生物组调控在小鼠多发性骨髓瘤模型中解偶联免疫检查点抑制剂的疗效与毒性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285849](https://pubmed.ncbi.nlm.nih.gov/41285849)
**期刊：** Nature communications
**PMID：** 41285849
**DOI：** 10.1038/s41467-025-65312-y

### 第一部分 原文与翻译

**英文原标题：** Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma.

**英文摘要原文：**
Smoldering multiple myeloma (SMM), which is in principle curable, may develop into life-threatening MM. Intestinal microbiota and gut-born T helper-17 (Th17) lymphocytes may contribute to this development, but the mechanisms are unclear. Here we demonstrate that administering the human commensal Prevotella melaninogenica to transgenic Vk*MYC mice that exhibit SMM-like phenotypes delays the evolution to full-blown MM. Mechanistically, P. melaninogenica increases the production of short-chain fatty acids (SCFA), thereby preventing the skewing of dendritic cells towards a pro-Th17 phenotype and subsequently accumulation of Th17 cells in the bone marrow of treated mice. P. melaninogenica or butyrate synergizes with anti-PD-L1 or anti-TIGIT to suppress myeloma progression by restraining Th17 cell expansion while inducing effector CD8 T cells. P. melaninogenica also attenuates IL-17-mediated skin lesions that mimic anti-PD-L1-induced adverse events. Our results thus suggest that gut microbiota modulation or SCFAs administration may represent treatment options for patients affected by plasma cell dyscrasias.

**中文摘要译文：**
冒烟型多发性骨髓瘤（SMM）原则上是可治愈的，但可能发展为危及生命的MM。肠道微生物群和源自肠道的T辅助17（Th17）淋巴细胞可能促进此过程，但其机制尚不明确。在本研究中，我们证明了给予表现出SMM样表型的转基因Vk*MYC小鼠人体共生菌——产黑色素普雷沃氏菌（Prevotella melaninogenica），可延缓其向完全型MM的演进。从机制上讲，产黑色素普雷沃氏菌能增加短链脂肪酸（SCFA）的产生，从而阻止树突状细胞向促Th17表型分化，并抑制Th17细胞在经治疗小鼠骨髓中的积聚。产黑色素普雷沃氏菌或丁酸盐与抗PD-L1或抗TIGIT疗法协同作用，通过抑制Th17细胞扩增同时诱导效应CD8+ T细胞，从而抑制骨髓瘤的进展。产黑色素普雷沃氏菌还能减轻IL-17介导的皮肤损伤，这种损伤模拟了抗PD-L1疗法诱导的不良事件。因此，我们的研究结果表明，调节肠道微生物群或补充SCFA可能为浆细胞恶液质患者提供新的治疗选择。

### 第二部分 AI 大师评价

本研究旨在探讨肠道微生物调控对多发性骨髓瘤（MM）进展及免疫检查点抑制剂（ICI）疗效与毒性的影响。研究团队通过在MM小鼠模型中引入特定的人体共生菌——产黑色素普雷沃氏菌，揭示了其通过产生短链脂肪酸（SCFA）来抑制促炎性Th17细胞，从而延缓MM进展的关键机制。该研究的重大创新在于，它不仅证明了该菌能增强ICI的抗肿瘤效果，还同时减轻了其相关的毒副作用，实现了“增效减毒”的双重目标。这一发现为浆细胞疾病的治疗提供了极具前景的新策略，即通过精准的微生物干预来优化免疫治疗。

---

## 4. 比较转录组图谱作为一种辅助手段用于罕见肾癌的复杂分类

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285844](https://pubmed.ncbi.nlm.nih.gov/41285844)
**期刊：** Nature communications
**PMID：** 41285844
**DOI：** 10.1038/s41467-025-65303-z

### 第一部分 原文与翻译

**英文原标题：** Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers.

**英文摘要原文：**
There is a great unmet medical need for development of molecularly characterizing modalities to assist in the complex classification of rare kidney cancers, some of which are diagnosed as unclassified renal cell carcinoma (unclassified RCC) due to complex histology. Here we show utility of the comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers. Whereas whole genome sequencing (WGS) of 52 rare kidney cancers identifies very few clinically significant variants in a subset of cases, unsupervised clustering results of RNA-seq data from 219 renal tumors including 140 rare kidney cancers are largely consistent with the histological classification based on WHO2022 classification. Additionally, the comparative transcriptome atlas may provide an opportunity to define the molecular characteristics of unclassified RCC and might predict patient outcome. These findings support the comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers.

**中文摘要译文：**
在辅助罕见肾癌的复杂分类方面，开发分子特征鉴定手段存在巨大的未满足医疗需求，其中一些罕见肾癌因组织学形态复杂而被诊断为未分类肾细胞癌（unclassified RCC）。在此，我们展示了比较转录组图谱作为一种辅助手段在罕见肾癌复杂分类中的应用价值。对52例罕见肾癌进行的全基因组测序（WGS）仅在部分病例中发现了极少数具有临床意义的变异，而对包括140例罕见肾癌在内的219例肾肿瘤的RNA测序（RNA-seq）数据进行无监督聚类分析，其结果与基于WHO 2022年分类标准的组织学分类高度一致。此外，比较转录组图谱可能为界定未分类肾细胞癌的分子特征提供机会，并可能预测患者的预后。这些发现支持将比较转录组图谱作为一种辅助手段用于罕见肾癌的复杂分类。

### 第二部分 AI 大师评价

该研究针对罕见肾癌，特别是组织学复杂的未分类肾细胞癌（RCC）分类困难的临床痛点，旨在建立一种有效的分子辅助诊断工具。研究创新性地构建了比较转录组图谱，并将其与全基因组测序（WGS）进行对比，发现基于RNA测序的无监督聚类分析在分类上与WHO标准高度一致，优于WGS。此研究不仅为未分类肾细胞癌的分子特征界定和预后预测提供了新途径，也证明了转录组学在解决疑难肾癌诊断中的巨大临床应用价值，有望提升诊断的精准性。

---

## 5. 可解释人工智能通过凝血-炎症谱揭示脓毒症异质性，以用于预后评估与风险分层

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285832](https://pubmed.ncbi.nlm.nih.gov/41285832)
**期刊：** Nature communications
**PMID：** 41285832
**DOI：** 10.1038/s41467-025-65365-z

### 第一部分 原文与翻译

**英文原标题：** Explainable AI unravels sepsis heterogeneity via coagulation-inflammation profiles for prognosis and stratification.

**英文摘要原文：**
Sepsis is a leading cause of hospital mortality, and its significant heterogeneity complicates prognosis and stratification. To address this challenge, we developed an explainable artificial intelligence prognostic model (SepsisFormer, a transformer-based neural network) and an automated risk-stratification tool (SMART) for sepsis. In a multi-center retrospective study of 12,408 sepsis patients, SepsisFormer achieved high predictive accuracy (AUC: 0.9301, sensitivity: 0.9346, and specificity: 0.8312). SMART (AUC: 0.7360) surpassed most established scoring systems. Seven coagulation-inflammatory routine laboratory measurements and patient age were identified to classify patients' four risk levels (mild, moderate, severe, dangerous) and two subphenotypes (CIS1 and CIS2), each with distinct clinical characteristics and mortality rates. Notably, patients with moderate/severe levels or CIS2 derive more significant benefits from anticoagulant treatment. Our work, therefore, offers a set of simple, real-time executable tools for sepsis heterogeneity, demonstrating the potential to enhance sepsis clinical practice globally, particularly in resource-constrained healthcare settings.

**中文摘要译文：**
脓毒症是导致医院死亡的主要原因，其显著的异质性使得预后评估和风险分层变得复杂。为应对这一挑战，我们开发了一种可解释的人工智能预后模型（SepsisFormer，一种基于Transformer的神经网络）和一种自动化的脓毒症风险分层工具（SMART）。在一项包含12408名脓毒症患者的多中心回顾性研究中，SepsisFormer实现了高预测准确性（AUC: 0.9301, 敏感性: 0.9346, 特异性: 0.8312）。SMART工具（AUC: 0.7360）的表现优于大多数已有的评分系统。研究确定了七项凝血-炎症常规实验室检测指标和患者年龄，可将患者分为四个风险等级（轻度、中度、重度、危险）和两种亚型（CIS1和CIS2），每种等级和亚型都具有独特的临床特征和死亡率。值得注意的是，中/重度风险等级或CIS2亚型的患者能从抗凝治疗中获得更显著的益处。因此，我们的研究为解决脓毒症异质性问题提供了一套简单、可实时执行的工具，展示了其在全球范围内（尤其是在资源有限的医疗环境中）提升脓毒症临床实践的潜力。

### 第二部分 AI 大师评价

本研究利用可解释人工智能（XAI）技术，旨在解决脓毒症异质性导致的预后和分层难题。研究团队开发了SepsisFormer预后模型和SMART分层工具，仅基于年龄和七项常规凝血-炎症指标，便能精准地将患者划分为不同风险亚型。其关键发现不仅验证了模型的高准确性，更揭示了特定亚型（如CIS2）患者可能从抗凝治疗中获益更多，为精准治疗提供了直接证据。这项工作的创新性在于将复杂的AI模型转化为临床上简单、可解释且实时可用的工具，对于指导脓毒症的个体化治疗、优化医疗资源分配具有重要的临床转化价值。

---

## 6. 靶向CREB3L2介导的脂质代谢可克服乐伐替尼耐药并延缓肝细胞癌的进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285809](https://pubmed.ncbi.nlm.nih.gov/41285809)
**期刊：** Cell death & disease
**PMID：** 41285809
**DOI：** 10.1038/s41419-025-08250-3

### 第一部分 原文与翻译

**英文原标题：** Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma.

**英文摘要原文：**
When hepatocellular carcinoma (HCC) cells exhibit malignant biological behaviors, lipid metabolic reprogramming occurs concomitantly. Thus, identifying regulators of metabolic reprogramming offers new potential targets for therapy. In this study, we investigated the mechanisms by which Cyclic adenosine monophosphate-responsive element binding protein 3-like 2(CREB3L2) influences HCC progression and contributes to lenvatinib resistance through modulation of lipid metabolism. Up-regulated expression of CREB3L2 was observed in numerous HCC cohorts and associated with poor survival prognosis of patients. Furthermore, CREB3L2 could facilitate the proliferation and metastatic capacity of HCC cells both in vitro and in vivo. It was found that CREB3L2 influences the proliferation and metastasis of HCC cells by up-regulating sterol regulatory element binding protein 1 (SREBP1), a vital regulatory factor of lipid synthesis for fatty acid production. Additionally, CREB3L2 enhances SREBP1 protein expression and stability through increased acetylation mediated by histone acetyltransferase-1(HAT1). Importantly, targeting CREB3L2 in combination with lenvatinib significantly reduced lenvatinib resistance, inhibiting the progression of CREB3L2 high-expressing HCC tumors. These findings suggest that the CREB3L2/HAT1/SREBP1 regulatory axis drives lenvatinib resistance and HCC progression by impacting lipid metabolism. Targeting CREB3L2 alongside lenvatinib improves the efficacy of treating HCC.

**中文摘要译文：**
当肝细胞癌（HCC）细胞表现出恶性生物学行为时，常伴随发生脂质代谢重编程。因此，识别代谢重编程的调控因子可为治疗提供新的潜在靶点。在本研究中，我们探讨了环磷酸腺苷反应元件结合蛋白3样蛋白2（CREB3L2）通过调节脂质代谢影响HCC进展并导致乐伐替尼耐药的机制。在众多HCC队列中观察到CREB3L2的表达上调，并与患者的不良生存预后相关。此外，CREB3L2在体外和体内均能促进HCC细胞的增殖和转移能力。研究发现，CREB3L2通过上调固醇调节元件结合蛋白1（SREBP1）来影响HCC细胞的增殖和转移，SREBP1是脂肪酸生成过程中脂质合成的关键调控因子。此外，CREB3L2通过组蛋白乙酰转移酶-1（HAT1）介导的乙酰化作用增强SREBP1蛋白的表达和稳定性。重要的是，靶向CREB3L2联合乐伐替尼能显著降低乐伐替尼的耐药性，从而抑制高表达CREB3L2的HCC肿瘤的进展。这些发现表明，CREB3L2/HAT1/SREBP1调控轴通过影响脂质代谢驱动乐伐替尼耐药和HCC进展。靶向CREB3L2联合乐伐替尼可提高治疗HCC的疗效。

### 第二部分 AI 大师评价

本研究旨在阐明CREB3L2在肝细胞癌（HCC）进展和乐伐替尼耐药中的作用机制。研究通过体内外实验，关键性地揭示了CREB3L2通过HAT1介导的乙酰化作用稳定并上调SREBP1，进而激活脂质代谢，促进肿瘤恶性进展。其创新之处在于首次阐明了“CREB3L2/HAT1/SREBP1”这一调控新轴线，为理解乐伐替尼耐药提供了全新的分子视角，并提出了靶向CREB3L2联合乐伐替尼的增效治疗策略，具有重要的临床转化潜力。

---

## 7. 靶向TIMM23克服骨肉瘤化疗耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285805](https://pubmed.ncbi.nlm.nih.gov/41285805)
**期刊：** Cell death & disease
**PMID：** 41285805
**DOI：** 10.1038/s41419-025-08106-w

### 第一部分 原文与翻译

**英文原标题：** Targeting TIMM23 to overcome osteosarcoma chemoresistance.

**英文摘要原文：**
Osteosarcoma (OS) is a malignant tumor whose chemoresistance severely compromises therapeutic efficacy. This study aims to investigate the molecular mechanism by which TIMM23 mediates M2 polarization of macrophages through mitophagy and regulates TIMM23-PARGP1 fusion gene expression and chemoresistance in OS. Single-cell transcriptomic analysis revealed a strong interaction between macrophages and tumor cells. By integrating bulk RNA sequencing data and weighted gene co-expression network analysis (WGCNA) co-expression network analysis, we identified TIMM23 as a key gene associated with macrophage polarization. Using STAR-Fusion, we further detected the TIMM23-PARGP1 fusion gene, which was validated via fluorescence in situ hybridization (FISH). CRISPR/Cas9 was employed to generate TIMM23-knockout macrophages, and a lentiviral system was used to create TIMM23-overexpressing macrophages. Flow cytometry demonstrated that TIMM23 promotes M2 polarization, while confocal and transmission electron microscopy confirmed its role in regulating mitophagy in M2 macrophages. These findings indicate that TIMM23 promotes M2 polarization through mitophagy modulation. Next, a co-culture model of macrophages and OS cells was established. MTT, Cell Counting Kit-8 (CCK-8), EdU, Transwell, and TUNEL assays were performed to evaluate tumor cell behavior and chemosensitivity. The results showed that TIMM23-induced M2 polarization upregulated TIMM23-PARGP1 expression in OS cells, thereby enhancing their proliferation, migration, and invasion while inhibiting apoptosis and reducing the effectiveness of chemotherapeutic agents. In vivo experiments further confirmed the role of TIMM23 in promoting M2 polarization and fusion gene expression, leading to increased chemoresistance and tumor growth. In conclusion, TIMM23 enhances OS chemoresistance and tumor progression by promoting M2 macrophage polarization via mitophagy and upregulating TIMM23-PARGP1 fusion gene expression. Graphical Abstract. Molecular mechanism diagram illustrating the involvement of TIMM23 in mitophagy-mediated M2 polarization of macrophages and the impact of TIMM23-PARGP1 fusion gene on chemoresistance in OS (Created with BioRender.com).

**中文摘要译文：**
骨肉瘤（OS）是一种恶性肿瘤，其化疗耐药性严重影响治疗效果。本研究旨在探讨TIMM23通过线粒体自噬介导巨噬细胞M2极化，并调控骨肉瘤中TIMM23-PARGP1融合基因表达及化疗耐药的分子机制。单细胞转录组学分析揭示了巨噬细胞与肿瘤细胞之间存在强烈的相互作用。通过整合批量RNA测序数据和加权基因共表达网络分析（WGCNA），我们鉴定出TIMM23是与巨噬细胞极化相关的关键基因。利用STAR-Fusion，我们进一步检测到TIMM23-PARGP1融合基因，并通过荧光原位杂交（FISH）技术进行了验证。我们采用CRISPR/Cas9技术构建了TIMM23敲除的巨噬细胞，并使用慢病毒系统构建了过表达TIMM23的巨噬细胞。流式细胞术证明TIMM23促进M2极化，而共聚焦显微镜和透射电子显微镜证实了其在M2巨噬细胞中调控线粒体自噬的作用。这些发现表明，TIMM23通过调控线粒体自噬促进M2极化。接下来，我们建立了巨噬细胞与骨肉瘤细胞的共培养模型。通过MTT、细胞计数试剂盒-8（CCK-8）、EdU、Transwell和TUNEL实验，评估了肿瘤细胞的行为和化疗敏感性。结果显示，TIMM23诱导的M2极化上调了骨肉瘤细胞中TIMM23-PARGP1的表达，从而增强了其增殖、迁移和侵袭能力，同时抑制了细胞凋亡并降低了化疗药物的疗效。体内实验进一步证实了TIMM23在促进M2极化和融合基因表达中的作用，进而导致化疗耐药性增加和肿瘤生长。总之，TIMM23通过线粒体自噬促进巨噬细胞M2极化，并上调TIMM23-PARGP1融合基因的表达，从而增强骨肉瘤的化疗耐药性和肿瘤进展。图文摘要：分子机制图解，展示了TIMM23参与线粒体自噬介导的巨噬细胞M2极化，以及TIMM23-PARGP1融合基因对骨肉瘤化疗耐药性的影响（由BioRender.com创建）。

### 第二部分 AI 大师评价

本研究旨在阐明TIMM23在骨肉瘤化疗耐药中的作用机制。研究者综合运用单细胞转录组学、基因编辑和体内外共培养模型等前沿技术，关键性地发现TIMM23通过调控线粒体自噬驱动巨噬细胞向M2型极化。更具创新性的是，研究首次揭示了这种极化的M2巨噬细胞能诱导骨肉瘤细胞中产生一种新的TIMM23-PARGP1融合基因，该融合基因是导致肿瘤化疗耐药和恶性进展的核心因素。这项研究不仅揭示了肿瘤微环境中一条全新的细胞间通讯与基因调控通路，也为克服骨肉瘤耐药性提供了极具潜力的治疗新靶点。

---

## 8. 53BP1-RIF1与DNA-PKcs在多样的染色体断裂修复结局中表现出独特的遗传相互作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285797](https://pubmed.ncbi.nlm.nih.gov/41285797)
**期刊：** Nature communications
**PMID：** 41285797
**DOI：** 10.1038/s41467-025-65329-3

### 第一部分 原文与翻译

**英文原标题：** 53BP1-RIF1 and DNA-PKcs show distinct genetic interactions with diverse chromosomal break repair outcomes.

**英文摘要原文：**
53BP1 accumulates at DNA double strand breaks (DSBs) and is implicated in non-homologous end joining (NHEJ), but the genetic interplay of 53BP1 with the NHEJ pathway (e.g., DNA-PKcs) is poorly understood. We examine blunt DSB NHEJ of Cas9 DSBs, which is dependent on core NHEJ factors, and find that loss of 53BP1 does not affect such repair but causes a reduction when combined with DNA-PKcs disruption. In contrast, disrupting 53BP1 and DNA-PKcs, alone and together, has similar effects on the type of deletion mutation (increase in microhomology deletions). We find similar effects with RIF1, such that 53BP1-RIF1 appear to play a backup role for DNA-PKcs during blunt DSB NHEJ, but function in the same pathway to suppress microhomology deletions. Finally, DNA-PKcs kinase inhibition causes increased radiosensitivity and homology-directed repair that is not additive with loss of 53BP1. Altogether, 53BP1-RIF1 and DNA-PKcs show distinct genetic interactions with diverse DSB repair outcomes.

**中文摘要译文：**
53BP1在DNA双链断裂（DSBs）处积聚，并参与非同源末端连接（NHEJ）过程，但53BP1与NHEJ通路（如DNA-PKcs）的遗传相互作用尚不明确。我们研究了依赖于核心NHEJ因子的Cas9诱导的平末端DSB的NHEJ修复，发现53BP1的缺失不影响此类修复，但当与DNA-PKcs功能破坏相结合时会导致修复效率降低。相反，在缺失突变类型方面（微同源性缺失增加），单独或同时破坏53BP1和DNA-PKcs具有相似的效果。我们在RIF1上也发现了类似的效果，表明53BP1-RIF1在平末端DSB的NHEJ修复中似乎扮演着DNA-PKcs的备用角色，但在抑制微同源性缺失方面则在同一通路中发挥作用。最后，DNA-PKcs激酶抑制导致放射敏感性和同源指导修复的增加，这种效应与53BP1的缺失没有累加效应。总而言之，53BP1-RIF1和DNA-PKcs在不同的DSB修复结局中表现出独特的遗传相互作用。

### 第二部分 AI 大师评价

本研究旨在深入解析DNA双链断裂修复过程中，关键蛋白53BP1-RIF1与非同源末端连接（NHEJ）核心因子DNA-PKcs之间复杂的遗传相互作用。通过运用Cas9基因编辑技术和药物抑制等方法，研究揭示了53BP1-RIF1在平末端NHEJ修复中扮演DNA-PKcs的“备用”角色，但在抑制微同源介导的末端连接方面则与DNA-PKcs协同作用。这一发现精准区分了二者在不同修复场景下的功能独特性与合作性，不仅深化了对基因组稳定性维持机制的理解，也为开发更精准的肿瘤放疗增敏剂或靶向治疗策略提供了重要的理论依据。

---

## 9. 白细胞介素-18受体α的高表达与严重呼吸道病毒病相关，并界定了一类细胞毒性特征降低的T细胞

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285788](https://pubmed.ncbi.nlm.nih.gov/41285788)
**期刊：** Nature communications
**PMID：** 41285788
**DOI：** 10.1038/s41467-025-65262-5

### 第一部分 原文与翻译

**英文原标题：** High expression of interleukin-18 receptor alpha correlates with severe respiratory viral disease and defines T cells with reduced cytotoxic signatures.

**英文摘要原文：**
Hyperactivated immunity underpins severe outcomes of respiratory viral infections, yet specific immune perturbations are ill-defined. Our recent findings identified OLAH (oleoyl-ACP-hydrolase) as a driver of life-threatening viral diseases. In the same patient cohorts, we now identify the gene encoding IL-18Rα chain (IL18R1), as being highly expressed in life-threatening influenza, COVID-19, RSV and multisystem inflammatory syndrome in children (MIS-C) and demonstrate markedly elevated surface protein IL-18Rα expression on CD8 T cells in these infections. Using a mouse model of severe influenza, we further show that high IL-18Rα expression on effector T cells is associated with increased disease severity. We find that IL-18Rα expression on CD8 T cells is inversely associated with cytotoxicity-related genes, including granzyme A, granzyme B, perforin, Eomes, and KLRG-1. Our study demonstrates that IL-18Rα is associated with severe and fatal respiratory disease outcomes and proposes the use of IL-18Rα as a potential biomarker for severe respiratory viral disease.

**中文摘要译文：**
过度激活的免疫反应是呼吸道病毒感染导致严重后果的基础，但具体的免疫紊乱机制尚不明确。我们近期的研究发现OLAH（油酰-ACP-水解酶）是危及生命的病毒性疾病的驱动因素。在相同的患者队列中，我们现在发现编码IL-18Rα链的基因（IL18R1）在危及生命的流感、COVID-19、RSV和儿童多系统炎症综合征（MIS-C）中高度表达，并证明在这些感染中CD8 T细胞表面的IL-18Rα蛋白表达显著升高。利用重症流感小鼠模型，我们进一步表明效应T细胞上IL-18Rα的高表达与疾病严重程度增加有关。我们发现，CD8 T细胞上的IL-18Rα表达与细胞毒性相关基因（包括颗粒酶A、颗粒酶B、穿孔素、Eomes和KLRG-1）的表达呈负相关。我们的研究表明，IL-18Rα与严重和致命的呼吸道疾病结局相关，并提议将IL-18Rα作为严重呼吸道病毒性疾病的潜在生物标志物。

### 第二部分 AI 大师评价

本研究旨在探究白细胞介素-18受体α（IL-18Rα）在严重呼吸道病毒感染中的作用。研究者通过分析多种病毒感染的患者队列及重症流感小鼠模型，发现IL-18Rα在重症患者的CD8 T细胞上显著高表达，且与疾病严重程度正相关。其核心发现是将IL-18Rα的高表达与T细胞细胞毒性相关基因的下调直接关联，揭示了其在免疫功能障碍中的潜在角色。这项工作不仅为理解病毒感染导致重症化的免疫机制提供了新视角，也明确提出IL-18Rα可作为预测疾病严重程度的潜在生物标志物，具有重要的临床转化价值。

---

## 10. 非同源末端连接通过不同机制修复双链断裂的每一条链

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285786](https://pubmed.ncbi.nlm.nih.gov/41285786)
**期刊：** Nature communications
**PMID：** 41285786
**DOI：** 10.1038/s41467-025-66528-8

### 第一部分 原文与翻译

**英文原标题：** Nonhomologous end-joining uses distinct mechanisms to repair each strand of a double strand break.

**英文摘要原文：**
Nonhomologous end-joining repairs chromosomal double strand breaks, but it is unknown whether both strands are repaired by this pathway, and if one strand break's repair path impacts the other. Here, we show that nonhomologous end-joining employs both of two a priori possible strategies. Strand breaks that can be directly ligated are joined near-simultaneously, with no effect of one strand break's repair path on the other. More complex end structures require obligatorily ordered repair. The first strand to be repaired is used as template for repair of the opposite/second strand break, with the latter repair reaction occurring fastest when also coupled to nonhomologous end-joining. Enforced asymmetry in repair of each strand break can extend to the gap-filling polymerase employed, and whether the polymerases incorporate RNA or DNA. Our results resolve questions about pathway mechanism and identify a requirement for flexibility of the nonhomologous end-joining machinery for efficient repair of both strand breaks within diverse cellular double strand breaks.

**中文摘要译文：**
非同源末端连接修复染色体双链断裂，但目前尚不清楚两条链是否都由该途径修复，以及一条链断裂的修复路径是否会影响另一条。在这里，我们证明了非同源末端连接采用了两种先验可能的策略。可以被直接连接的链断裂几乎是同时连接的，其中一条链断裂的修复路径对另一条没有影响。更复杂的末端结构则需要强制性的有序修复。第一条被修复的链被用作修复对侧/第二条链断裂的模板，当后者也与非同源末端连接耦合时，其修复反应发生得最快。每条链断裂修复中的强制不对称性可以延伸到所使用的间隙填充聚合酶，以及聚合酶是掺入RNA还是DNA。我们的研究结果解决了关于该途径机制的问题，并指出了非同源末端连接机制需要具备灵活性，以有效修复细胞内各种双链断裂中的两条链断裂。

### 第二部分 AI 大师评价

该研究旨在揭示非同源末端连接（NHEJ）修复双链断裂（DSB）时，其对两条单链的具体修复机制。研究发现，NHEJ会根据断裂末端结构的不同，采用两种截然不同的策略：对于可直接连接的断裂，两条链的修复近乎同步且相互独立；而对于复杂末端，修复则呈现出强制性的先后顺序和不对称性，甚至涉及不同的聚合酶。这项发现深刻揭示了NHEJ通路在单链层面的灵活性与精确调控机制，对于理解DNA损伤修复的保真度、癌症发生以及基因编辑技术的优化具有重要的科研价值。

---

## 11. T细胞幼淋巴细胞白血病患者的流行病学与生存分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285750](https://pubmed.ncbi.nlm.nih.gov/41285750)
**期刊：** Blood cancer journal
**PMID：** 41285750
**DOI：** 10.1038/s41408-025-01428-0

### 第一部分 原文与翻译

**英文原标题：** Epidemiology and survival of patients with T-cell prolymphocytic leukemia.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究旨在系统分析T细胞幼淋巴细胞白血病（T-PLL）这一罕见恶性肿瘤的流行病学特征及患者的生存状况。鉴于T-PLL的罕见性，此类基于大样本人群的研究对于揭示其发病规律、预后因素及真实世界中的治疗效果至关重要。尽管暂无摘要信息，但本研究可能通过分析大型数据库，为临床医生提供了关于该疾病自然史的宝贵数据，并为未来临床试验设计和患者管理策略提供了重要参考基线。

---

## 12. 一个调控ERα配体结合域构象的三元转换开关模型

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285747](https://pubmed.ncbi.nlm.nih.gov/41285747)
**期刊：** Nature communications
**PMID：** 41285747
**DOI：** 10.1038/s41467-025-65323-9

### 第一部分 原文与翻译

**英文原标题：** A ternary switch model governing ERα ligand binding domain conformation.

**英文摘要原文：**
The transcription factor estrogen receptor α is the primary driver of ER+ breast cancer progression and a target of multiple FDA-approved anticancer drugs. Ligand-dependent activity of ERα is determined by helix-12 conformation within the ligand binding domain. However, how helix-12 transitions from an unliganded (apo) state to active (estrogen-bound) or inactive (SERM/SERD-bound) states remains unresolved. Here, we present the crystal structure of an apo estrogen receptor α ligand binding domain from the teleost Melanotaenia fluviatilis, revealing a third distinct helix-12 conformation. Structural mass spectrometry and molecular dynamics simulations reveal that apo helix-12 is maintained in a stable and distinct conformation prior to ligand binding. Clashes between ligand and evolutionarily conserved residues L525, L536 and L540 displace helix-12, to promote activation or inactivation of the receptor. The crystal structure further reveals that breast cancer-associated mutations, Y537S and D538G, disrupt residue contacts critical for stabilising apo helix-12 conformation. We propose a model whereby helix-12 functions as a ternary molecular switch to determine receptor activity. These findings provide critical insights into the ligand-dependent and -independent regulation of estrogen receptor α and have significant implications for therapeutic intervention.

**中文摘要译文：**
转录因子雌激素受体α（ERα）是ER阳性乳腺癌进展的主要驱动因素，也是多种FDA批准的抗癌药物的靶点。ERα的配体依赖性活性由其配体结合域内的helix-12（第12号螺旋）构象决定。然而，helix-12如何从未结合配体（apo）状态转变为活性（雌激素结合）或非活性（SERM/SERD结合）状态仍是未解之谜。在此，我们展示了来自硬骨鱼（Melanotaenia fluviatilis）的apo状态雌激素受体α配体结合域的晶体结构，揭示了第三种独特的helix-12构象。结构质谱和分子动力学模拟显示，在配体结合之前，apo状态的helix-12维持在一个稳定且独特的构象中。配体与进化上保守的残基L525、L536和L540之间的空间冲突导致helix-12移位，从而促进受体的激活或失活。该晶体结构进一步揭示，与乳腺癌相关的突变Y537S和D538G破坏了对稳定apo状态下helix-12构象至关重要的残基间接触。我们提出了一个模型，其中helix-12作为一个三元分子开关来决定受体活性。这些发现为雌激素受体α的配体依赖性及非依赖性调控提供了关键见解，并对治疗干预具有重要意义。

### 第二部分 AI 大师评价

本研究旨在揭示雌激素受体α（ERα）关键功能区helix-12在不同配体结合状态下的构象转换机制。研究团队综合运用X射线晶体学、结构质谱和分子动力学模拟技术，首次解析了未结合配体（apo）状态下ERα的新构象，发现其存在一种不同于传统激活或抑制状态的、独特的第三种稳定构象。基于此，研究者创新性地提出了一个‘三元分子开关’模型，阐明了helix-12如何在apo、激活和失活三种状态间转换，并揭示了特定乳腺癌突变破坏该开关稳定性的分子基础。这一发现深化了对ERα活性调控机制的理解，为开发针对ER+乳腺癌的新型精准治疗药物提供了重要的结构生物学依据和理论框架。

---

## 13. IGF2BP3以m6A依赖的方式调节EMP1稳定性并激活TGF-β通路以促进胰腺癌侵袭

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285728](https://pubmed.ncbi.nlm.nih.gov/41285728)
**期刊：** Cell death & disease
**PMID：** 41285728
**DOI：** 10.1038/s41419-025-08155-1

### 第一部分 原文与翻译

**英文原标题：** IGF2BP3 regulates EMP1 stability in an mA-dependent manner and activates the TGF-β pathway to promote pancreatic cancer invasion.

**英文摘要原文：**
Local invasion is considered a premonitor of tumor metastasis which cause curative difficulties and undesired prognosis in patients with Pancreatic ductal adenocarcinoma (PDAC). The importance of mRNA N6-methyladenosine (mA) modification during tumor invasion is controversial as it plays distinct roles which mainly attributed to different mA reader proteins exert function. In current study, the level of mA expression in PDAC was analyzed by IHC and ELISA, all mA-regulated genes in PDAC detected by qPCR. The downstream gene EMP1 was screened by analyzing IGF2BP3 knockdown RNA-seq, IGF2BP3-RIP, MeRIP-seq, and PDAC-survival related genes. And mA modification sites of EMP1 RNA was verified by MeRIP-qPCR, RIP-qPCR, and dual luciferase assays. EMP1-binding protein VASP was identified by mass spectrometry. Cell migration and invasive activity were detected using cytoskeletal staining, scratch assay, transwell assay, subcutaneous tumor and lung metastasis models. Finally, prognosis and immune microenvironment was analyzed in PDAC by IHC and multiple immunofluorescence staining. This work shows that mA reader IGF2BP3 is remarkably upregulated in local invasion PDAC and indicates worse prognosis of patients. Mechanistically, IGF2BP3 recognized mA-modified EMP1 mRNAs to prolong stability of them, which inhibits the hindrance of SMAD7 to SMAD3/4 phosphorylation by promoting the binding of VASP and SMAD7. Finally, a tight correlation of the local invasion/IGF2BP3/EMP1 and infiltration of immune cells in the tumor microenvironment is evidenced in clinical PDAC. In conclusions, IGF2BP3 functions as an invasion driver that induces PDAC development via the EMP1/TGF-β axis. And IGF2BP3/EMP1 axis may be involved in regulating microenvironmental remodeling in pancreatic cancer.

**中文摘要译文：**
局部侵袭被认为是胰腺导管腺癌（PDAC）患者肿瘤转移的前兆，它会导致治疗困难和不良预后。在肿瘤侵袭过程中，mRNA N6-甲基腺苷（m6A）修饰的重要性尚存争议，因为它发挥着不同的作用，这主要归因于不同的m6A阅读蛋白所发挥的功能。在本研究中，通过IHC和ELISA分析了PDAC中m6A的表达水平，并通过qPCR检测了PDAC中所有受m6A调控的基因。通过分析IGF2BP3敲低后的RNA-seq、IGF2BP3-RIP、MeRIP-seq以及与PDAC生存相关的基因，筛选出了下游基因EMP1。并且，通过MeRIP-qPCR、RIP-qPCR和双荧光素酶测定验证了EMP1 RNA的m6A修饰位点。通过质谱法鉴定了EMP1的结合蛋白VASP。利用细胞骨架染色、划痕实验、Transwell实验、皮下肿瘤和肺转移模型检测了细胞的迁移和侵袭活性。最后，通过IHC和多重免疫荧光染色分析了PDAC患者的预后及肿瘤免疫微环境。本研究表明，m6A阅读蛋白IGF2BP3在局部侵袭性PDAC中显著上调，并预示着患者较差的预后。机制上，IGF2BP3识别经m6A修饰的EMP1 mRNA以延长其稳定性，这通过促进VASP与SMAD7的结合，抑制了SMAD7对SMAD3/4磷酸化的阻碍作用。最终，在临床PDAC样本中证实了局部侵袭、IGF2BP3/EMP1与肿瘤微环境中免疫细胞浸润之间的紧密关联。总之，IGF2BP3作为一个侵袭驱动因子，通过EMP1/TGF-β轴诱导PDAC的发展。并且，IGF2BP3/EMP1轴可能参与调控胰腺癌的微环境重塑。

### 第二部分 AI 大师评价

本研究聚焦于胰腺癌侵袭转移的关键科学问题，通过结合多组学分析、分子细胞生物学实验及临床样本验证，系统揭示了m6A阅读蛋白IGF2BP3的核心作用。其关键发现是，IGF2BP3通过识别并稳定m6A修饰的EMP1 mRNA，进而激活TGF-β信号通路，最终促进胰腺癌的侵袭。这项工作的创新性在于明确了一条从RNA表观遗传修饰到关键促癌信号通路的完整调控链（IGF2BP3/EMP1/TGF-β），不仅为理解胰腺癌的侵袭机制提供了新视角，也提示IGF2BP3/EMP1轴可能成为潜在的预后生物标志物和治疗靶点。

---

## 14. 欧洲白血病网 (European LeukemiaNet) 关于骨髓纤维化新药安全性和有效性评价的标准

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285724](https://pubmed.ncbi.nlm.nih.gov/41285724)
**期刊：** Blood cancer journal
**PMID：** 41285724
**DOI：** 10.1038/s41408-025-01381-y

### 第一部分 原文与翻译

**英文原标题：** European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.

**英文摘要原文：**
Most myelofibrosis (MF) drug approvals by Health Authorities are based on 1 or 2 outcome measures such as spleen volume reduction and/or improved quality of life. This 1-2 dimensional approach fails to capture the clinical complexity of MF. A European LeukemiaNet (ELN) task force developed a composite endpoint that allows multiple outcomes to be simultaneously measured. The panel used the Desirability Of Outcome Ranking (DOOR) method to assign 25 outcomes into 4 quartiles based on a multi-dimensional desirability score and build a 5-layer composite outcome named Desirability of Myelofibrosis Outcomes (DEMYO). Outcome operational definitions were tested by Delphi consensus, and correlations with survival were validated by a literature review. The outcomes assigned to the first two quartiles were negatively correlated with leukemia-free survival and survival. DEMYO comprehensively captures relevant MF clinical features and meaningful endpoints. Despite DEMYO requiring validation based on available trial data, it is expected to improve the quality of Health Authority approvals for new drugs for MF.

**中文摘要译文：**
卫生监管机构对大多数骨髓纤维化 (MF) 药物的批准是基于1到2项结局指标，例如脾脏体积缩小和/或生活质量改善。这种一至二维的评估方法未能捕捉骨髓纤维化的临床复杂性。欧洲白血病网 (ELN) 的一个工作组开发了一种复合终点，能够同时衡量多个结局。该专家组采用结局期望排序 (DOOR) 方法，根据一个多维期望评分，将25项结局分为4个四分位数组，并构建了一个名为“骨髓纤维化结局期望” (DEMYO) 的五层复合结局。结局的操作性定义通过德尔菲法共识进行了检验，其与生存率的相关性通过文献回顾得到了验证。被分配到前两个四分位数组的结局与无白血病生存期和总生存期呈负相关。DEMYО全面地捕捉了骨髓纤维化的相关临床特征和有意义的终点。尽管DEMYО仍需基于现有的试验数据进行验证，但它有望提高卫生监管机构对骨髓纤维化新药批准的质量。

### 第二部分 AI 大师评价

该研究针对当前骨髓纤维化 (MF) 新药审批标准过于单一（仅关注脾脏缩小和生活质量）的局限性，提出了一个创新性的多维评价体系。研究团队通过欧洲白血病网 (ELN) 专家共识，运用结局期望排序 (DOOR) 方法，成功构建了一个名为 DEMYO 的复合终点指标。该指标整合了25项临床结局，其分层与患者的生存预后显著相关，从而能更全面地反映药物的综合临床获益。尽管 DEMYO 尚需临床试验数据的进一步验证，但它为未来 MF 新药的研发和监管审批提供了更科学、更贴近临床复杂性的评估框架，具有重要的指导价值。

---

## 15. 利用机械穿孔技术实现CRISPR/Cas9介导的滋养层细胞基因编辑，为子痫前期研究提供新见解

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285723](https://pubmed.ncbi.nlm.nih.gov/41285723)
**期刊：** Cell death & disease
**PMID：** 41285723
**DOI：** 10.1038/s41419-025-08200-z

### 第一部分 原文与翻译

**英文原标题：** CRISPR/Cas9-mediated gene editing in trophoblast cells via mechanoporation for preeclampsia insight.

**英文摘要原文：**
Preeclampsia is a severe pregnancy complication marked by impaired trophoblast function and abnormal placental development, leading to significant maternal and fetal morbidity. FK506-binding protein-like (FKBPL) has been identified as a potential biomarker as it is significantly downregulated in early pregnancy stages of women who progress to develop preeclampsia. However, editing the Fkbpl gene in trophoblast cells to create a model of preeclampsia using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology is challenging due to inefficient delivery, leading to low editing efficiency and reduced cell viability. To address these challenges, we developed a cost-effective and minimally invasive mechanoporation system using micro-engineered filters to deliver CRISPR/Cas9 plasmid DNA (pDNA) targeting the Fkbpl gene into trophoblast cells. This approach successfully generated cell lines with a 38% knockout (K/O) of Fkbpl expression, significantly reducing cell migration (wildtype (WT): 28.77% ± 4.7 vs. 38% K/O: 4.95% ± 0.8, wound closure, **p < 0.01) and proliferation (WT: 1.26 ± 0.06 vs. 38% K/O: 0.81 ± 0.01, ****p < 0.0001). Lower Fkbpl-K/O efficiency of 17% showed a similar reduction in cell proliferation as the 38% K/O clone. Although a full Fkbpl-K/O in the ACH-3P first-trimester trophoblast cell line was not achieved, the partial K/O provided valuable insights into Fkbpl's role in trophoblast function relevant to preeclampsia pathogenesis. Moreover, treatment with mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) or MSC-sEVs did not restore migratory capacity in Fkbpl-deficient cells (p = 0.14). MSC-sEVs increased proliferation in WT ACH-3P cells at 1 µg (p < 0.05) and 2 µg (p < 0.01) doses, however, were not effective in either 17% or 38% Fkbpl-K/O clones, suggesting that FKBPL is an important mechanism of MSC-sEV-mediated therapeutic effect in trophoblasts in the context of preeclampsia. This study advances gene-editing techniques in placental biology and proposes new therapeutic strategies and mechanisms for pregnancy-related complications.A Schematic overview of CRISPR/Cas9 plasmid delivery using microfiltroporation compared to gold standard electroporation and lipofection technologies in trophoblast cells. A CRISPR/Cas9 plasmid targeting Fkbpl was delivered to the first trimester trophoblast cell line, ACH-3P. Cells were sorted according to green fluorescence protein (GFP) expression, expanded and assessed for changes in cell function using proliferation and migration assays. B Actual images of the isopore silicon nitride (SiN) microfilters used in this study and diagram of cell membrane dynamics in response to mechanoporation. This figure was created with Biorender.com. CRISPR clustered regularly interspaced short palindromic repeats, EP electroporation, MFP microfiltroporation.

**中文摘要译文：**
子痫前期是一种严重的妊娠并发症，其特征是滋养层细胞功能受损和胎盘发育异常，导致显著的母婴患病率。FK506结合蛋白样蛋白（FKBPL）已被确定为一种潜在的生物标志物，因为它在后续发展为子痫前期的女性的早孕阶段显著下调。然而，由于递送效率低下，使用成簇规律间隔短回文重复序列（CRISPR）/CRISPR相关蛋白9（Cas9）技术在滋养层细胞中编辑Fkbpl基因以创建子痫前期模型具有挑战性，这会导致编辑效率低和细胞活力下降。为应对这些挑战，我们开发了一种成本效益高且微创的机械穿孔系统，利用微工程过滤器将靶向Fkbpl基因的CRISPR/Cas9质粒DNA（pDNA）递送至滋养层细胞。该方法成功生成了Fkbpl表达敲除率为38%的细胞系，并显著降低了细胞迁移（野生型（WT）：28.77% ± 4.7 vs. 38% K/O：4.95% ± 0.8，伤口愈合，**p < 0.01）和增殖（WT：1.26 ± 0.06 vs. 38% K/O：0.81 ± 0.01，****p < 0.0001）。敲除效率较低（17%）的Fkbpl-K/O克隆株在细胞增殖方面显示出与38% K/O克隆株相似的降低程度。尽管未能在早孕期滋养层细胞系ACH-3P中实现Fkbpl的完全敲除，但部分敲除为了解Fkbpl在与子痫前期发病机制相关的滋养层细胞功能中的作用提供了宝贵的见解。此外，使用间充质干细胞（MSC）来源的小细胞外囊泡（sEVs）或MSC-sEVs进行治疗，未能恢复Fkbpl缺陷细胞的迁移能力（p = 0.14）。MSC-sEVs在1 µg（p < 0.05）和2 µg（p < 0.01）剂量下能促进野生型ACH-3P细胞的增殖，但在17%或38% Fkbpl-K/O克隆株中均无效，这表明在子痫前期的背景下，FKBPL是MSC-sEV介导的对滋养层细胞治疗作用的一个重要机制。本研究推动了胎盘生物学中的基因编辑技术发展，并为妊娠相关并发症提出了新的治疗策略和机制。A. 使用微孔过滤穿孔技术与金标准电穿孔及脂质体转染技术在滋养层细胞中递送CRISPR/Cas9质粒的示意图。将一个靶向Fkbpl的CRISPR/Cas9质粒递送至早孕期滋养层细胞系ACH-3P。根据绿色荧光蛋白（GFP）的表达对细胞进行分选、扩增，并使用增殖和迁移实验评估细胞功能的变化。B. 本研究中使用的异孔氮化硅（SiN）微过滤器的实际图像以及细胞膜响应机械穿孔的动态图。此图由Biorender.com创建。CRISPR：成簇规律间隔短回文重复序列，EP：电穿孔，MFP：微孔过滤穿孔。

### 第二部分 AI 大师评价

本研究旨在解决滋养层细胞基因编辑的技术难题，创新性地采用机械穿孔技术递送CRISPR/Cas9系统，成功构建了子痫前期相关的FKBPL基因部分敲除模型。关键发现表明，FKBPL的下调会损害滋养层细胞的迁移与增殖，并且揭示了FKBPL可能是间充质干细胞外囊泡发挥治疗作用的关键靶点。尽管未能实现完全基因敲除，该研究不仅为子痫前期的病理机制研究提供了高效的细胞模型，也为探索新的治疗策略和靶点开辟了新方向，具有重要的科研价值。

---

## 16. 赖氨酸乳酸化在疾病中的作用：不止于组蛋白乳酸化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285721](https://pubmed.ncbi.nlm.nih.gov/41285721)
**期刊：** Cell death & disease
**PMID：** 41285721
**DOI：** 10.1038/s41419-025-08223-6

### 第一部分 原文与翻译

**英文原标题：** Lysine lactylation in diseases: beyond histone lactylation.

**英文摘要原文：**
Lactylation, a recently identified post-translational modification, was initially characterized as lysine residue modification in histone subunits that regulates gene transcription via epigenetic mechanisms. Elevated intracellular lactate has been shown to drive histone lysine lactylation (Kla), establishing its association with disease pathogenesis. Emerging evidence reveals that Kla modifications extend beyond histones to transcriptional regulators and cytoplasmic functional proteins. Unlike the broad transcriptional regulation mediated by histone lactylation, Kla modifications of functional proteins exert regulatory effects through both specific transcriptional modulation and direct functional alteration of target proteins, thereby precisely controlling biological processes. This review systematically examines the pathological implications of Kla modifications of functional proteins across multiple disease contexts, including inflammatory disorders, infectious diseases, neurological or cardiovascular pathologies, and oncological conditions. Our synthesis provides mechanistic insights into disease-associated Kla networks, facilitating therapeutic target discovery and pharmacological intervention strategies.

**中文摘要译文：**
乳酸化（Lactylation）作为一种新近发现的翻译后修饰，最初被鉴定为组蛋白亚基上的赖氨酸残基修饰，通过表观遗传机制调节基因转录。研究表明，细胞内乳酸水平升高可驱动组蛋白赖氨酸乳酸化（Kla），从而确立了其与疾病发病机制的关联。新出现的证据表明，Kla修饰的范围已超越组蛋白，延伸至转录调节因子和细胞质功能蛋白。与组蛋白乳酸化介导的广泛转录调控不同，功能蛋白的Kla修饰通过特异性转录调控和直接改变靶蛋白功能两种方式发挥调控作用，从而精确控制生物学过程。本篇综述系统性地探讨了功能蛋白的Kla修饰在多种疾病背景下的病理学意义，包括炎症性疾病、感染性疾病、神经或心血管病变以及肿瘤等。我们的综合论述为理解疾病相关的Kla网络提供了机制性见解，有助于治疗靶点的发现和药物干预策略的制定。

### 第二部分 AI 大师评价

该综述系统阐述了赖氨酸乳酸化（Kla）这一新兴翻译后修饰在疾病中的作用，并创新性地将焦点从经典的组蛋白修饰拓展至功能性非组蛋白。文章总结了Kla修饰在炎症、感染、心血管及肿瘤等多种疾病中，通过调控转录和直接改变蛋白功能来影响病理进程的关键机制。此项工作为深入理解疾病相关的Kla调控网络提供了宝贵的机制性见解，对开发靶向Kla通路的新型治疗策略具有重要的指导意义。

---

## 17. 缺氧肿瘤微环境中的坏死和凋亡脂肪细胞通过提供甘油三酯诱导头颈癌转移淋巴结的顺铂耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285714](https://pubmed.ncbi.nlm.nih.gov/41285714)
**期刊：** Cell death & disease
**PMID：** 41285714
**DOI：** 10.1038/s41419-025-08239-y

### 第一部分 原文与翻译

**英文原标题：** Necrotic and apoptotic adipocytes in the hypoxic tumor microenvironment supply triglycerides to induce cisplatin resistance in the metastatic lymph nodes of head and neck carcinoma.

**英文摘要原文：**
Metastatic lesions in cervical lymph nodes are generally less sensitive to induction chemotherapy than primary tumors, making cervical lymph node metastasis one of the most significant prognostic factors in head and neck squamous cell carcinoma (HNSCC). However, the underlying mechanism of cisplatin resistance in these lymph nodes remains unclear. Lipidomic analysis of 21 HNSCC patients revealed distinct lipid profiles between cervical lymph node metastases and primary tumors, with triglycerides notably enriched in the metastatic nodes, suggesting a critical role for adipocytes. Further investigation confirmed the presence of cancer-associated adipocytes within cervical lymph node metastases, which supply triglycerides to tumor cells. The hypoxic tumor microenvironment promotes apoptosis and necrosis in adipocytes, a process accelerated by hypoxic tumor cells, leading to increased triglyceride release. In HNSCC cells, triglycerides promote lipid droplet accumulation and enhance contact between lipid droplets and mitochondria via the interaction of perilipin-2 (PLIN2) and carnitine palmitoyltransferase-1A (CPT1A), thereby reversing cisplatin-induced rises in intracellular reactive oxygen species (ROS). In vivo, xenograft tumors located in adipocyte-rich regions showed larger volume and greater mass after cisplatin treatment. This study is the first to demonstrate that adipocytes are key components in cervical lymph node metastasis of HNSCC and are closely associated with cisplatin resistance. Mechanistically, the hypoxic tumor microenvironment facilitates crosstalk between tumor cells and adipocytes, increasing triglyceride supply from adipocytes. This, in turn, promotes lipid droplet-mitochondria contact in HNSCC cells through PLIN2-CPT1A binding, counteracting cisplatin-induced ROS elevation and contributing to chemoresistance.

**中文摘要译文：**
颈部淋巴结的转移性病灶通常对诱导化疗的敏感性低于原发肿瘤，这使得颈部淋巴结转移成为头颈部鳞状细胞癌（HNSCC）最重要的预后因素之一。然而，这些淋巴结中顺铂耐药的潜在机制仍不清楚。对21名HNSCC患者的脂质组学分析显示，颈部淋巴结转移灶与原发肿瘤之间存在显著不同的脂质谱，其中甘油三酯在转移性淋巴结中显著富集，这表明脂肪细胞发挥了关键作用。进一步的研究证实了颈部淋巴结转移灶内存在癌症相关脂肪细胞，这些细胞为肿瘤细胞提供甘油三酯。缺氧的肿瘤微环境促进脂肪细胞的凋亡和坏死，这一过程被缺氧的肿瘤细胞加速，导致甘油三酯释放增加。在HNSCC细胞中，甘油三酯通过perilipin-2（PLIN2）和肉碱棕榈酰转移酶-1A（CPT1A）的相互作用，促进脂滴积累并增强脂滴与线粒体之间的接触，从而逆转由顺铂诱导的细胞内活性氧（ROS）水平的升高。在体内实验中，位于富含脂肪细胞区域的异种移植肿瘤在顺铂治疗后显示出更大的体积和重量。本研究首次证明，脂肪细胞是HNSCC颈部淋巴结转移的关键组成部分，并与顺铂耐药性密切相关。从机制上讲，缺氧的肿瘤微环境促进了肿瘤细胞与脂肪细胞之间的串扰，增加了来自脂肪细胞的甘油三酯供应。这反过来又通过PLIN2-CPT1A的结合促进了HNSCC细胞中脂滴与线粒体的接触，从而抵消了顺铂诱导的ROS升高，并导致了化疗耐药。

### 第二部分 AI 大师评价

本研究旨在揭示头颈部鳞状细胞癌（HNSCC）转移淋巴结中顺铂耐药的潜在机制。研究人员通过脂质组学分析、细胞及动物模型实验，创新性地发现缺氧微环境中的脂肪细胞是诱导耐药的关键。其核心发现是，坏死和凋亡的脂肪细胞释放甘油三酯，肿瘤细胞摄取后通过PLIN2-CPT1A相互作用，增强脂滴与线粒体的偶联，进而拮抗顺铂诱导的活性氧（ROS）积累，最终导致化疗抵抗。这项研究首次阐明了脂肪细胞在HNSCC淋巴结转移灶耐药中的关键作用，为克服临床化疗耐药提供了新的靶点和思路。

---

## 18. ZFP36L1下调通过增强NHEJ DNA修复机制促进骨肉瘤的甲氨蝶呤耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285712](https://pubmed.ncbi.nlm.nih.gov/41285712)
**期刊：** Cell death & disease
**PMID：** 41285712
**DOI：** 10.1038/s41419-025-08217-4

### 第一部分 原文与翻译

**英文原标题：** Downregulation of ZFP36L1 contributes to methotrexate resistance in osteosarcoma through enhanced NHEJ DNA repair mechanisms.

**英文摘要原文：**
Chemotherapy resistance poses a significant challenge in the treatment of osteosarcoma. While DNA damage repair mechanisms play a crucial role in this resistance, effective intervention strategies remain limited. This study elucidates an intrinsic DNA damage repair mechanism in osteosarcoma cells treated with methotrexate (MTX) that can be effectively disrupted through the overexpression of ZFP36L1. Our findings indicate that ZFP36L1 expression is downregulated in MTX-resistant osteosarcoma cells. By overexpressing ZFP36L1 in osteosarcoma cell lines, we observed an increase in sensitivity to MTX. Further investigation revealed that the overexpression of ZFP36L1 reduces the efficiency of the DNA damage repair process, particularly by inhibiting the DCLRE1C-mediated non-homologous end joining (NHEJ) pathway. Through analysis of the 3' untranslated region (3'UTR) of DCLRE1C mRNA, we identified 8 potential AU-rich elements (AREs) that bind to ZFP36L1. We demonstrated that ZFP36L1 directly interacts with DCLRE1C mRNA, leading to its degradation. In summary, decreased ZFP36L1 expression serves as an inherent mechanism enabling osteosarcoma to develop resistance to MTX therapy. These results highlight ZFP36L1 as a promising therapeutic target for overcoming MTX chemoresistance in osteosarcoma.

**中文摘要译文：**
化疗耐药是骨肉瘤治疗中的一个重大挑战。尽管DNA损伤修复机制在这种耐药性中起着至关重要的作用，但有效的干预策略仍然有限。本研究阐明了用甲氨蝶呤（MTX）处理的骨肉瘤细胞中一种内在的DNA损伤修复机制，该机制可通过过表达ZFP36L1被有效破坏。我们的研究结果表明，ZFP36L1在MTX耐药的骨肉瘤细胞中表达下调。通过在骨肉瘤细胞系中过表达ZFP36L1，我们观察到细胞对MTX的敏感性增加。进一步的研究揭示，ZFP36L1的过表达降低了DNA损伤修复过程的效率，特别是通过抑制DCLRE1C介导的非同源末端连接（NHEJ）通路。通过分析DCLRE1C mRNA的3'非翻译区（3'UTR），我们鉴定了8个可能与ZFP36L1结合的富含AU的元件（AREs）。我们证明了ZFP36L1直接与DCLRE1C mRNA相互作用，导致其降解。总之，ZFP36L1表达的降低是骨肉瘤对MTX治疗产生耐药性的一种内在机制。这些结果凸显了ZFP36L1作为克服骨肉瘤MTX化疗耐药的一个有前景的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在揭示骨肉瘤对甲氨蝶呤（MTX）耐药的新机制。研究通过细胞与分子生物学手段，关键性地发现ZFP36L1的表达下调是导致耐药的核心因素。其创新之处在于，首次阐明了ZFP36L1通过直接结合并降解DCLRE1C mRNA，进而抑制NHEJ通路介导的DNA损伤修复，最终逆转耐药的分子通路。该发现不仅深化了对骨肉瘤耐药机制的理解，更将ZFP36L1确立为克服MTX耐药的一个极具潜力的治疗靶点，为临床干预提供了新的科学依据。

---

## 19. 以Tscm/Tcm细胞为主的异体抗BCMA CAR-T疗法治疗复发/难治性多发性骨髓瘤：临床前表征及1期临床试验的中期结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285709](https://pubmed.ncbi.nlm.nih.gov/41285709)
**期刊：** Nature communications
**PMID：** 41285709
**DOI：** 10.1038/s41467-025-65267-0

### 第一部分 原文与翻译

**英文原标题：** T-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial.

**英文摘要原文：**
Autologous CAR-T therapies targeting B-cell maturation antigen (BCMA) in relapsed/refractory multiple myeloma (RRMM) have demonstrated therapeutic clinical responses. Here, we present the characterization and interim Phase I data for P-BCMA-ALLO1, a T-predominant allogeneic CAR-T therapy targeting BCMA in heavily pretreated relapsed/refractory multiple myeloma. Preclinical analyses reveal a strong correlation between CD8 T phenotype and in vivo potency in mouse xenograft models. In early clinical data (NCT04960579), among the 11 of 33 evaluable patients who received enhanced lymphodepletion, 82% (9/11) responded, with 63.6% (7/11) achieving very good partial response (VGPR) or better. All patients started therapy a median of 1 day after enrollment, with every patient receiving P-BCMA-ALLO1 infusion, and resulting in a 100% intent-to-treat (ITT) rate with no use of bridging therapy. CRS was reported in 21.2% (7/33) across all cohorts, all grade ≤2. The median time to peak CAR-T cell expansion (T) was 10 days post-infusion. Consistent with preclinical findings, CAR-T cell expansion is accompanied by differentiation from a predominantly T phenotype to a T/T phenotype, with trafficking and persistence observed in bone marrow. These data suggest that a T cellular phenotype may offer significant advantages in efficacy, safety, and cellular persistence in the context of allogeneic CAR-T therapy. Clinical trial: NCT04960579.

**中文摘要译文：**
靶向B细胞成熟抗原（BCMA）的自体CAR-T疗法在治疗复发/难治性多发性骨髓瘤（RRMM）中已显示出治疗性临床反应。在此，我们报告了P-BCMA-ALLO1的表征和I期临床试验的中期数据，这是一种以Tscm/Tcm细胞为主的异体CAR-T疗法，用于治疗经过多线治疗的复发/难治性多发性骨髓瘤。临床前分析揭示，在小鼠异种移植模型中，CD8+ T细胞表型与体内效力之间存在强相关性。在早期临床数据（NCT04960579）中，33名可评估患者中接受了强化淋巴细胞清除方案的11名患者里，82%（9/11）的患者有应答，其中63.6%（7/11）的患者达到了非常好的部分缓解（VGPR）或更佳疗效。所有患者在入组后中位1天即开始治疗，每位患者都接受了P-BCMA-ALLO1输注，实现了100%的意向治疗（ITT）率，且未使用桥接治疗。在所有队列中，细胞因子释放综合征（CRS）的发生率为21.2%（7/33），且所有级别均≤2级。CAR-T细胞扩增达到峰值的中位时间为输注后10天。与临床前研究结果一致，CAR-T细胞的扩增伴随着其从以Tscm/Tcm表型为主向Tem/Teff表型分化，并在骨髓中观察到其归巢和持久存续。这些数据表明，一个Tscm/Tcm细胞表型可能在异体CAR-T疗法的背景下，于疗效、安全性和细胞持久性方面提供显著优势。临床试验编号：NCT04960579。

### 第二部分 AI 大师评价

本研究旨在评估一种以T细胞记忆干细胞/中央记忆T细胞（Tscm/Tcm）亚群为主的新型异体抗BCMA CAR-T疗法（P-BCMA-ALLO1）在治疗复发/难治性多发性骨髓瘤中的安全性和有效性。通过临床前研究和1期临床试验，研究发现该“现货型”疗法在经过强化淋巴细胞清除的患者中展现了高达82%的客观缓解率，且安全性良好。其核心创新在于证实了初始T细胞表型与体内疗效的强相关性，并观察到CAR-T细胞的有效扩增、分化及持久存续。尽管尚处早期阶段，但该研究为开发更高效、便捷的异体细胞疗法提供了关键的临床证据和重要的转化医学见解。

---

## 20. 靶向肿瘤浸润B细胞：癌症治疗的机制与进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285707](https://pubmed.ncbi.nlm.nih.gov/41285707)
**期刊：** Cell death & disease
**PMID：** 41285707
**DOI：** 10.1038/s41419-025-08254-z

### 第一部分 原文与翻译

**英文原标题：** Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy.

**英文摘要原文：**
The emergence of immunotherapy has heralded a new era in cancer treatment, with countless patients reaping the benefits of this innovative approach. While the majority of immunotherapy research has concentrated on T cells, there is a growing body of evidence highlighting the significant role of tumor-infiltrating B cells(TIL-Bs) in tumor immunity. This review synthesizes the potential mechanisms by which B cells contribute to tumor proliferation, metastasis, drug resistance, and angiogenesis. We provide a comprehensive analysis of the role of TIL-Bs within the tumor microenvironment(TME) and their impact on the cancer immune response, emphasizing their dual role as both allies and adversaries in the fight against cancer. To explain this phenomenon, we propose a dynamic regulatory framework of the TME targeting B cells, which indicates that the functions of B cells adjust in response to the dynamic changes of the tumor microenvironment. Understanding the mechanisms of B cell action within the TME is crucial for the development of targeted immunotherapies that leverage TIL-Bs. Finally, this article summarizes the latest advances in TIL-Bs in cancer immunotherapy and provides a historical overview of the evolution of immunotherapeutic strategies.

**中文摘要译文：**
免疫疗法的出现开启了癌症治疗的新纪元，无数患者从这一创新方法中获益。尽管大多数免疫疗法的研究集中于T细胞，但越来越多的证据凸显了肿瘤浸润B细胞（TIL-Bs）在肿瘤免疫中的重要作用。本篇综述综合阐述了B细胞促进肿瘤增殖、转移、耐药及血管生成的潜在机制。我们全面分析了TIL-Bs在肿瘤微环境（TME）中的作用及其对癌症免疫应答的影响，并强调了其在抗癌斗争中作为“盟友”与“敌人”的双重角色。为解释此现象，我们提出了一个靶向B细胞的TME动态调控框架，该框架指出B细胞的功能会随着肿瘤微环境的动态变化而调整。理解B细胞在TME内的作用机制对于开发利用TIL-Bs的靶向免疫疗法至关重要。最后，本文总结了TIL-Bs在癌症免疫治疗中的最新进展，并对免疫治疗策略的演变进行了历史性概述。

### 第二部分 AI 大师评价

该综述文章系统性地探讨了肿瘤浸润B细胞（TIL-Bs）在肿瘤免疫中的复杂角色，旨在阐明其促进或抑制肿瘤发展的双重作用机制。文章的核心亮点在于提出了一个动态调控框架，认为B细胞的功能并非一成不变，而是随肿瘤微环境的动态变化而适应性调整。该综述通过全面梳理B细胞在肿瘤增殖、转移、耐药中的作用及相关免疫疗法进展，为开发新型、更精准的靶向B细胞癌症免疫策略提供了重要的理论依据和前沿视角，对深化我们对肿瘤微环境复杂性的理解具有显著的科研价值。

---

## 21. Spanve：一种适用于大规模数据下游分析的空间可变基因统计方法

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41284930](https://pubmed.ncbi.nlm.nih.gov/41284930)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41284930
**DOI：** 10.1093/gpbjnl/qzaf111

### 第一部分 原文与翻译

**英文原标题：** Spanve: A Statistical Method for Downstream-friendly Spatially Variable Genes in Large-scale Data.

**英文摘要原文：**
Depicting gene expression in a spatial context through spatial transcriptomics is beneficial for inferring cellular mechanisms. Identifying spatially variable genes is a crucial step in leveraging spatial transcriptome data to understand intricate spatial dynamics. In this study, we developed Spanve, a nonparametric statistical method for detecting spatially variable genes in large-scale spatial transcriptomics datasets by quantifying expression differences between each spot or cell and its local neighbors. This method offers a nonparametric approach for identifying spatial dependencies in gene expression without distributional assumptions. Compared with existing methods, Spanve yields fewer false positives, leading to more accurate identification of spatially variable genes. Furthermore, Spanve improves the performance of downstream spatial transcriptomics analyses including spatial domain detection and cell type deconvolution. These results show the broad application potential of Spanve in advancing our understanding of spatial gene expression patterns within complex tissue microenvironments. Spanve is publicly available at https://github.com/zjupgx/Spanve and https://ngdc.cncb.ac.cn/biocode/tool/BT7724.

**中文摘要译文：**
通过空间转录组学在空间背景下描绘基因表达，有助于推断细胞机制。识别空间可变基因是利用空间转录组数据以理解复杂空间动态的关键步骤。本研究中，我们开发了一种名为Spanve的非参数统计方法，通过量化每个位点或细胞与其局部邻域之间的表达差异，来检测大规模空间转录组数据集中的空间可变基因。该方法提供了一种非参数途径，无需分布假设即可识别基因表达的空间依赖性。与现有方法相比，Spanve产生的假阳性更少，从而能更准确地识别空间可变基因。此外，Spanve还能提升包括空间域检测和细胞类型反卷积在内的下游空间转录组学分析的性能。这些结果表明，Spanve在促进我们理解复杂组织微环境中的空间基因表达模式方面具有广泛的应用潜力。Spanve已在 https://github.com/zjupgx/Spanve 和 https://ngdc.cncb.ac.cn/biocode/tool/BT7724 上公开发布。

### 第二部分 AI 大师评价

本研究旨在开发一种名为Spanve的新型非参数统计方法，用于在大规模空间转录组数据中精确识别空间可变基因。该方法通过比较邻近细胞或空间位点的基因表达差异，无需任何分布假设，从而提高了检测的准确性并减少了假阳性。其核心创新在于其下游分析友好性，能显著提升空间域检测和细胞类型反卷积等分析的性能。因此，Spanve为深入解析复杂组织微环境中的基因表达空间异质性提供了强大的计算工具，具有重要的科研应用价值。

---

## 22. scATAnno：一种用于单细胞ATAC测序数据的自动化细胞类型注释工具

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41284927](https://pubmed.ncbi.nlm.nih.gov/41284927)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41284927
**DOI：** 10.1093/gpbjnl/qzaf108

### 第一部分 原文与翻译

**英文原标题：** scATAnno: Automated Cell Type Annotation for Single-cell ATAC Sequencing Data.

**英文摘要原文：**
Recent advances in single-cell epigenomic techniques have created a growing demand for scATAC-seq analysis. One key analysis task is to determine cell type identity based on the epigenetic data. We introduce scATAnno, a python package designed to automatically annotate scATAC-seq data using large-scale scATAC-seq reference atlases. This workflow generates the reference atlases from publicly available datasets enabling accurate cell type annotation by integrating query data with reference atlases, without the use of scRNA-seq data. To enhance annotation accuracy, we have incorporated KNN-based and weighted distance-based uncertainty scores to effectively detect cell populations within the query data that are distinct from all cell types in the reference data. We compare and benchmark scATAnno against 5 other published approaches for cell annotation, demonstrating superior performance in multiple data sets and metrics. We showcase the utility of scATAnno across multiple datasets, including peripheral blood mononuclear cell (PBMC), triple negative breast cancer (TNBC), and basal cell carcinoma (BCC), and demonstrate that scATAnno accurately annotates cell types across conditions. Overall, scATAnno is a useful tool for scATAC-seq reference building and cell type annotation in scATAC-seq data and can aid in the interpretation of new scATAC-seq datasets in complex biological systems. scATAnno is available online at https://scatanno-main.readthedocs.io/.

**中文摘要译文：**
近年来，单细胞表观基因组技术的进步使得对scATAC-seq分析的需求日益增长。其中一项关键的分析任务是基于表观遗传数据确定细胞类型。我们介绍scATAnno，这是一个旨在使用大规模scATAC-seq参考图谱自动注释scATAC-seq数据的Python软件包。该工作流从公开可用的数据集中生成参考图谱，通过将查询数据与参考图谱整合，无需使用scRNA-seq数据即可实现准确的细胞类型注释。为了提高注释的准确性，我们引入了基于K最近邻（KNN）和加权距离的不确定性评分，以有效检测查询数据中与参考数据中所有细胞类型均不相同的细胞群体。我们将scATAnno与其他5种已发表的细胞注释方法进行了比较和基准测试，结果表明其在多个数据集和评价指标上均表现出优越的性能。我们展示了scATAnno在多个数据集中的实用性，包括外周血单核细胞（PBMC）、三阴性乳腺癌（TNBC）和基底细胞癌（BCC），并证明scATAnno能够在不同条件下准确注释细胞类型。总的来说，scATAnno是scATAC-seq数据中用于参考图谱构建和细胞类型注释的有用工具，能够辅助解释复杂生物系统中的新scATAC-seq数据集。scATAnno可通过https://scatanno-main.readthedocs.io/在线获取。

### 第二部分 AI 大师评价

该研究针对单细胞ATAC测序（scATAC-seq）数据分析中的核心挑战，即细胞类型注释，开发了一款名为scATAnno的自动化Python工具。其核心创新在于构建并利用大规模scATAC-seq参考图谱，实现了不依赖scRNA-seq数据的直接注释，并通过引入不确定性评分来识别新的细胞亚群，显著提高了注释的准确性和适用性。该工具在多种生物样本（包括血液和肿瘤）中展示了优于现有方法的性能，为复杂疾病的表观遗传学研究提供了强大助力，具有重要的科研应用价值。

---

## 23. 开发一种高度分化的大鼠脑类器官模型，用于探索胶质母细胞瘤的侵袭动态与治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41284925](https://pubmed.ncbi.nlm.nih.gov/41284925)
**期刊：** Neuro-oncology
**PMID：** 41284925
**DOI：** 10.1093/neuonc/noaf271

### 第一部分 原文与翻译

**英文原标题：** Development of a highly differentiated rat brain organoid model for exploring glioblastoma invasion dynamics and therapy.

**英文摘要原文：**
BACKGROUND: Human brain organoids (BOs) are important models for studying early brain development and neurological disorders. While techniques for creating BOs are advancing, they remain developmental structures. Therefore, when human BOs are used to studying glioma-host interactions, the tumor behavior may be influenced by the BO-developmental microenvironment. Here, we describe the maturation of rat brain organoids (rBOs) into fully differentiated BOs and demonstrate their value as a model for studying glioblastoma (GB)-host interactions and their use in testing therapeutic interventions.

MATERIALS AND METHODS: rBOs were obtained from fetal cortical brains on the 18th day of gestation. Transcriptomic, proteomic, and metabolomic analyses determined their differentiation into maturity. Their developmental trajectory was compared to human BOs derived from induced pluripotent stem cells as well as to rat brain development. Tumor-rBO interactions, including invasion parameters and therapeutic interactions, were studied using five human GB models.

RESULTS: The rBOs develop into organized structures with myelinated neurons, oligodendrocytes, synapses, and glial cells, mirroring the rat brain development. GB invasion in rBOs matched those observed in orthotopic xenografts, enabling real-time assessment of invasion metrics: cellular heterogeneity, single-cell invasion speed, and tumor progression. The BOs had a strong impact on GB transcriptional activity and can be used to study therapeutic interventions. The rBO differentiation status influenced GB invasion capacity.

CONCLUSIONS: The rBOs serve as an effective target brain structure for studying GB invasion parameters and for evaluating therapeutic interventions. Their rapid development into mature brain tissue makes rBOs a valuable brain avatar system for studying tumor-host interactions.

**中文摘要译文：**
背景：人脑类器官（BOs）是研究早期大脑发育和神经系统疾病的重要模型。尽管BOs的构建技术在不断进步，但它们仍是发育阶段的结构。因此，当人BOs被用于研究胶质瘤-宿主相互作用时，肿瘤行为可能会受到BOs发育微环境的影响。在此，我们描述了大鼠脑类器官（rBOs）成熟为完全分化的BOs的过程，并展示了其作为研究胶质母细胞瘤（GB）-宿主相互作用以及测试治疗干预措施模型的价值。

材料与方法：rBOs取自妊娠第18天的胎鼠大脑皮层。通过转录组学、蛋白质组学和代谢组学分析确定其分化成熟。我们将其发育轨迹与源自诱导性多能干细胞的人BOs以及大鼠大脑的实际发育过程进行了比较。使用五种人GB模型研究了肿瘤与rBO的相互作用，包括侵袭参数和治疗性相互作用。

结果：rBOs发育成为具有髓鞘化神经元、少突胶质细胞、突触和胶质细胞的有序结构，这反映了大鼠大脑的发育过程。rBOs中的GB侵袭情况与在原位异种移植模型中观察到的一致，从而能够实时评估侵袭指标：细胞异质性、单细胞侵袭速度和肿瘤进展。这些BOs对GB的转录活性有显著影响，可用于研究治疗性干预。rBO的分化状态影响了GB的侵袭能力。

结论：rBOs可作为研究GB侵袭参数和评估治疗干预的有效靶脑结构。它们能快速发育成成熟的脑组织，这使得rBOs成为研究肿瘤-宿主相互作用的一个有价值的脑“化身”系统。

### 第二部分 AI 大师评价

本研究旨在解决现有脑类器官模型发育不成熟的局限性，成功开发了一种能快速形成髓鞘化等成熟结构的高度分化大鼠脑类器官（rBO）模型。研究通过多组学分析验证了其成熟度，并证实了其在模拟胶质母细胞瘤（GB）侵袭动态方面与体内原位异种移植模型具有高度一致性。该模型的创新之处在于提供了一个更接近生理状态的、可用于实时观察肿瘤-宿主相互作用及评估治疗反应的体外平台，这不仅为神经肿瘤学研究提供了强大的新工具，也为个性化药物筛选开辟了新的可能性。

---

## 24. 既往移植与艾基仑赛在多发性骨髓瘤中的应用：一项基于CIBMTR数据的二次分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41284631](https://pubmed.ncbi.nlm.nih.gov/41284631)
**期刊：** Blood
**PMID：** 41284631
**DOI：** 10.1182/blood.2025031426

### 第一部分 原文与翻译

**英文原标题：** Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.

**英文摘要原文：**
N/A.

**中文摘要译文：**
原文摘要信息缺失（N/A）。

### 第二部分 AI 大师评价

本研究基于CIBMTR的大型数据库进行二次分析，旨在探究既往移植史对多发性骨髓瘤患者接受艾基仑赛（idecabtagene vicleucel）CAR-T细胞治疗结局的影响。该研究的价值在于利用真实世界数据，为临床上如何衔接和排序移植与CAR-T这两种关键疗法提供证据。由于缺乏摘要信息，无法深入评价其具体发现、研究方法和局限性，但其研究方向对于指导治疗决策具有重要的临床参考价值。

---

## 25. 双重抑制FACT和RRM2可抑制癌组蛋白H2BG53D驱动的胰腺导管腺癌的进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41284383](https://pubmed.ncbi.nlm.nih.gov/41284383)
**期刊：** Cell reports
**PMID：** 41284383
**DOI：** 10.1016/j.celrep.2025.116596

### 第一部分 原文与翻译

**英文原标题：** Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohistone H2BG53D.

**英文摘要原文：**
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with frequent genetic mutations. We previously reported the identification of the histone H2BG53D mutation and revealed that this mutation destabilizes nucleosomes and promotes cell migration. However, how H2BG53D impacts chromatin and its significance in PDAC development remain unknown. Using genetically engineered mouse models, we demonstrate that H2BG53D promotes PDAC initiation and metastasis. Moreover, H2BG53D elevates the interaction between nucleosomes and the facilitates chromatin transcription (FACT) complex. FACT depletion reverses transcriptional changes and oncogenic effects induced by H2BG53D. In search of therapeutic strategies, our genome-wide CRISPR-Cas9 screen identified ribonucleotide reductase regulatory subunit M2 (RRM2) as a druggable target for H2BG53D-PDAC. Remarkably, dual inhibition of RRM2 and FACT markedly inhibits PDAC development and significantly prolongs the survival of H2BG53D-PDAC mice. This study deciphers the roles and mechanisms of H2BG53D in PDAC and proposes a promising therapeutic strategy for this aggressive cancer.

**中文摘要译文：**
胰腺导管腺癌（PDAC）是一种高度致命的癌症，常伴有频繁的基因突变。我们先前报道了组蛋白H2BG53D突变的鉴定，并揭示了该突变会破坏核小体的稳定性并促进细胞迁移。然而，H2BG53D如何影响染色质及其在PDAC发展中的重要性仍然未知。通过使用基因工程小鼠模型，我们证明了H2BG53D会促进PDAC的发生和转移。此外，H2BG53D增强了核小体与染色质转录促进（FACT）复合物之间的相互作用。耗尽FACT可逆转由H2BG53D诱导的转录变化和致癌效应。在寻找治疗策略的过程中，我们的全基因组CRISPR-Cas9筛选确定了核糖核苷酸还原酶调节亚基M2（RRM2）是H2BG53D-PDAC的一个可成药靶点。值得注意的是，双重抑制RRM2和FACT能显著抑制PDAC的发展，并显著延长H2BG53D-PDAC小鼠的生存期。本研究阐明了H2BG53D在PDAC中的作用和机制，并为这种侵袭性癌症提出了一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明癌组蛋白H2BG53D在胰腺导管腺癌（PDAC）中的致癌机制，并探索针对性的治疗策略。研究团队利用基因工程小鼠模型和CRISPR-Cas9筛选技术，发现H2BG53D通过增强与FACT复合物的相互作用来促进PDAC的发生与转移。该研究的创新之处在于，不仅揭示了一种新型表观遗传驱动因素的作用机理，还基于此发现了一个极具潜力的“双靶点”联合抑制方案（FACT和RRM2），为治疗携带特定突变的侵袭性PDAC提供了坚实的实验依据和新的临床转化方向。

---

## 26. 靶向HER2跨越不同癌症亚型的泛肿瘤治疗策略新进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41283902](https://pubmed.ncbi.nlm.nih.gov/41283902)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41283902
**DOI：** 10.1158/1078-0432.CCR-25-1982

### 第一部分 原文与翻译

**英文原标题：** Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.

**英文摘要原文：**
HER2 (human epidermal growth factor receptor 2) is an established therapeutic target in multiple solid tumors, particularly breast and gastric cancers. Significant advancements have been made in the development HER2-targeted therapies, including monoclonal antibodies, tyrosine kinase inhibitors, antibody-drug conjugates (ADCs), and novel bispecific antibodies. These agents have revolutionized the treatment landscape for HER2-positive metastatic cancers, resulting in improved progression-free and overall survival, and quality of life for patients. Beyond breast and gastric cancers, HER2 expression/amplification has been observed in other solid tumors, such as colorectal lung, bladder, ovarian, and biliary tract cancers, as well as offering new opportunities for personalized therapy in a larger patient population. In this review, we highlight the current state of HER2-targeted treatment strategies across HER2-expressing solid tumors, discussing the clinical efficacy, adverse event profiles, and challenges of existing therapies. We explore emerging treatment approaches, including novel agents such as HER2-targeting ADCs, combination therapies, and strategies to overcome resistance mechanisms. Additionally, we examine the role of HER2 expression heterogeneity, biomarker-driven patient selection, and diagnostic tools for patient selection and optimization of the treatment outcomes. This review also investigates ongoing challenges in expanding HER2-targeted therapies, including addressing intrinsic and acquired resistance, and tailoring strategies to low HER2-expressing or HER2-mutant tumors. Lastly, we provide insights into future directions, emphasizing the importance of precision oncology to broaden the therapeutic opportunities of HER2-targeted therapies across diverse HER2-driven malignancies.

**中文摘要译文：**
HER2（人表皮生长因子受体2）是多种实体瘤中一个已确立的治疗靶点，尤其是在乳腺癌和胃癌中。靶向HER2的疗法开发已取得显著进展，包括单克隆抗体、酪氨酸激酶抑制剂、抗体药物偶联物（ADC）以及新型双特异性抗体。这些药物彻底改变了HER2阳性转移性癌症的治疗格局，为患者带来了更长的无进展生存期、总生存期以及更高的生活质量。除乳腺癌和胃癌外，在结直肠癌、肺癌、膀胱癌、卵巢癌和胆道癌等其他实体瘤中也观察到HER2的表达/扩增，这为更广泛的患者群体提供了个性化治疗的新机遇。在这篇综述中，我们重点阐述了针对表达HER2的各类实体瘤的靶向治疗策略现状，讨论了现有疗法的临床疗效、不良事件特征及所面临的挑战。我们探索了新兴的治疗方法，包括靶向HER2的ADC等新型药物、联合疗法以及克服耐药机制的策略。此外，我们还审视了HER2表达异质性的作用、生物标志物驱动的患者选择，以及用于患者筛选和优化治疗结局的诊断工具。本综述还探讨了在推广HER2靶向疗法过程中持续存在的挑战，包括解决内在性和获得性耐药问题，以及针对HER2低表达或HER2突变肿瘤量身定制治疗策略。最后，我们对未来方向提供了见解，强调了精准肿瘤学在拓宽HER2靶向疗法应用于多种HER2驱动恶性肿瘤中的治疗机会的重要性。

### 第二部分 AI 大师评价

该综述全面概述了靶向HER2疗法在多种实体瘤中的应用现状与未来方向，其核心价值在于系统性地梳理了从传统乳腺癌、胃癌到结直肠癌、肺癌等多种癌症中HER2靶向治疗的临床证据与挑战。文章不仅总结了现有药物的疗效与安全性，更前瞻性地探讨了新型ADC药物、联合疗法以及如何克服耐药、应对HER2低表达和突变等前沿问题。对于临床医生和研究人员而言，这篇文献提供了一份宝贵的泛癌种治疗策略参考，对推动精准肿瘤学发展具有重要的指导意义。

---

## 27. RBMX2将牛分枝杆菌感染与上皮-间质转化及肺癌进展联系起来

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41277807](https://pubmed.ncbi.nlm.nih.gov/41277807)
**期刊：** eLife
**PMID：** 41277807
**DOI：** 10.7554/eLife.107132

### 第一部分 原文与翻译

**英文原标题：** RBMX2 links M. bovis infection to epithelial-mesenchymal transition and lung cancer progression.

**英文摘要原文：**
Tuberculosis (TB) is a complex disease caused by the interaction of pathogen, host, and environmental factors. In 2022, TB affected 10.6 million people and caused 1.3 million deaths globally. In high-burden zoonotic TB regions, M. bovis accounts for ~10% of human TB cases. The immune evasion and latency of M. bovis hinder understanding of host responses. Here, we identify RNA-binding motif protein X-linked 2 (RBMX2) as a novel host factor facilitating M. bovis infection. RBMX2 expression is significantly upregulated in multiple cell types, including EBL, BoMac, bovine alveolar primary cells, and human A549 cells. Multi-omics analyses, cell adhesion assays, and ChIP-PCR demonstrate that RBMX2 suppresses cell adhesion and tight junctions while enhancing M. bovis adhesion and invasion via p65 signaling. Integrated transcriptomic, proteomic, and metabolomic data reveal that RBMX2 regulates epithelial-mesenchymal transition (EMT), a process linked to cancer progression. TIMER2.0 analysis shows elevated RBMX2 expression in lung adenocarcinoma and lung squamous cell carcinoma tissues, validated by immunofluorescence. Using an M. bovis-induced BoMac-EBL EMT model and H1299 cells, we show that RBMX2 promotes EMT through p65/MMP-9 pathway activation. Collectively, RBMX2 is a novel host factor that enhances M. bovis infection and drives infection-induced EMT. These findings provide new insight into TB pathogenesis and highlight RBMX2 as a potential target for TB vaccine and therapeutic development.

**中文摘要译文：**
结核病（TB）是一种由病原体、宿主和环境因素相互作用引起的复杂疾病。2022年，全球有1060万人罹患结核病，并导致130万人死亡。在人畜共患结核病高负担地区，牛分枝杆菌（M. bovis）约占人类结核病例的10%。牛分枝杆菌的免疫逃逸和潜伏特性阻碍了对其宿主反应的理解。在此，我们鉴定出RNA结合基序蛋白X连锁2（RBMX2）是一种促进牛分枝杆菌感染的新型宿主因子。在包括EBL、BoMac、牛肺泡原代细胞和人A549细胞在内的多种细胞类型中，RBMX2的表达显著上调。多组学分析、细胞粘附实验和ChIP-PCR表明，RBMX2在抑制细胞粘附和紧密连接的同时，通过p65信号通路增强牛分枝杆菌的粘附和侵袭。整合的转录组学、蛋白质组学和代谢组学数据显示，RBMX2调控上皮-间质转化（EMT），这是一个与癌症进展相关的过程。TIMER2.0分析显示，RBMX2在肺腺癌和肺鳞状细胞癌组织中表达升高，并经免疫荧光法验证。利用牛分枝杆菌诱导的BoMac-EBL EMT模型和H1299细胞，我们证明RBMX2通过激活p65/MMP-9通路促进EMT。总而言之，RBMX2是一种新型宿主因子，它能增强牛分枝杆菌感染并驱动感染诱导的EMT。这些发现为结核病的发病机制提供了新的见解，并凸显了RBMX2作为结核病疫苗和治疗开发的潜在靶点。

### 第二部分 AI 大师评价

本研究旨在揭示宿主因子RBMX2在牛分枝杆菌感染中的作用及其与肺部疾病进展的关联。研究综合运用了多组学分析、细胞实验和分子生物学技术，关键发现RBMX2不仅能通过p65信号通路促进牛分枝杆菌的粘附与侵袭，还能通过p65/MMP-9通路驱动上皮-间质转化（EMT）。这项工作的创新之处在于首次将RBMX2确立为连接结核菌感染与EMT（一种与癌症发展密切相关的过程）的关键分子，为理解结核病与肺癌之间的潜在病理联系提供了新的分子机制，并提示RBMX2可能成为结核病治疗和肿瘤干预的潜在新靶点。

---

## 28. MODOMICS：RNA修饰及相关信息数据库的2025年更新与20周年纪念

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41277531](https://pubmed.ncbi.nlm.nih.gov/41277531)
**期刊：** Nucleic acids research
**PMID：** 41277531
**DOI：** 10.1093/nar/gkaf1284

### 第一部分 原文与翻译

**英文原标题：** MODOMICS: a database of RNA modifications and related information. 2025 update and 20th anniversary.

**英文摘要原文：**
MODOMICS is the reference database of RNA modifications and related information, integrating chemical, biochemical, structural, and functional data. In this 2025 update, marking the 20th anniversary of MODOMICS, the database has been significantly expanded in scope and depth. The RNA sequence section now includes transcriptome-wide data generated in collaboration with Sci-ModoM, a quantitative resource of high-throughput epitranscriptomic datasets, enabling the representation of >48 000 transcripts with high-confidence modification annotations. The catalog of modified residues was improved with systematic curation, and addition of new computational descriptors derived from quantum mechanical calculations. An all-versus-all similarity analysis of chemical structures was performed, and the results are provided as an interactive similarity graph to explore chemical relationships among modifications. The protein section has been updated with newly characterized enzymes and expanded annotations of modification pathways, supported by an improved evidence and reliability framework. Together, these advances further strengthen MODOMICS as a comprehensive and reliable community resource, serving as both a reference and a platform for discovery in the rapidly developing field of epitranscriptomics. MODOMICS is available at https://iimcb.genesilico.pl/modomics/.

**中文摘要译文：**
MODOMICS 是一个整合了化学、生物化学、结构和功能数据的RNA修饰及相关信息的参考数据库。在本次纪念MODOMICS创立20周年的2025年更新中，该数据库在范围和深度上都得到了显著扩展。RNA序列部分现已包含与Sci-ModoM（一个高通量表观转录组学数据集的定量资源库）合作生成的转录组范围数据，从而能够呈现超过48,000个带有高可信度修饰注释的转录本。修饰残基目录通过系统性整理和增补源自量子力学计算的新计算描述符而得到改进。研究人员进行了一项化学结构的全对全相似性分析，其结果以交互式相似性图谱的形式提供，用于探索不同修饰之间的化学关系。蛋白质部分也已更新，纳入了新表征的酶，并扩展了对修饰通路的注释，这些都由一个经过改进的证据与可靠性框架提供支持。总而言之，这些进展进一步巩固了MODOMICS作为一个全面、可靠的社区资源的地位，在快速发展的表观转录组学领域中，它既是参考基准，也是一个促进发现的平台。MODOMICS 可通过以下网址访问：https://iimcb.genesilico.pl/modomics/。

### 第二部分 AI 大师评价

本文介绍了RNA修饰领域的权威参考数据库MODOMICS在其成立20周年之际发布的2025年重大更新。此次更新通过整合高通量表观转录组学数据，极大地扩展了RNA序列的覆盖范围和修饰注释的精确性，并引入了基于量子力学计算的描述符和化学结构相似性图谱等创新工具。这些增强功能不仅提升了数据库的深度与广度，更巩固了其作为表观转录组学研究核心资源的地位，为该领域的科研人员提供了更强大、可靠的数据支持和探索平台。

---

## 29. RBP2GO 2.0：整合疾病关联与序列特征以探索RNA结合蛋白的功能

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41277526](https://pubmed.ncbi.nlm.nih.gov/41277526)
**期刊：** Nucleic acids research
**PMID：** 41277526
**DOI：** 10.1093/nar/gkaf1258

### 第一部分 原文与翻译

**英文原标题：** RBP2GO 2.0: Integrating disease associations and sequence features to explore RNA-binding protein functions.

**英文摘要原文：**
RNA-binding proteins (RBPs) play key roles in a wide range of biological processes and human diseases. Here, we updated RBP2GO, a comprehensive resource on RBPs, their binding partners, and functions across 13 species. The database RBP2GO 2.0 now provides additional information on disease ontology to better relate RBP functions to their impact in human diseases. It also integrates knowledge from new proteome-wide RBP studies and provides specific information on sequence features through intuitive cartoon-style representations, such as associated RNA-binding peptides, when available. Existing eCLIP/iCLIP datasets from ENCODE have been linked to the corresponding proteins, along with RNA dependence information from the R-DeeP database. Protein characterization is further supported by two scores, the RBP2GO Score and the RBP2GO Composite Score, which reflect the probability that the protein binds to RNA. The scores are now visualized using violin plot distributions for the whole proteome of each species. The redesigned user interface enables intuitive searches for protein names, gene ontology terms, disease ontology terms, and protein domains directly from the Home page and provides extended, versatile search options via the Advanced Search module. RBP2GO 2.0 serves as a valuable tool for investigating new RBP functions and is publicly accessible at https://RBP2GOv2.dkfz.de.

**中文摘要译文：**
RNA结合蛋白（RBPs）在广泛的生物过程和人类疾病中扮演着关键角色。在此，我们更新了RBP2GO——一个关于13个物种中RBPs、其结合伴侣及功能的综合资源库。该数据库RBP2GO 2.0现在提供了关于疾病本体论的额外信息，以便更好地将RBP的功能与其在人类疾病中的影响联系起来。它还整合了来自新的蛋白质组范围RBP研究的知识，并通过直观的卡通风格图示提供序列特征的具体信息，例如在可用时提供相关的RNA结合肽段信息。来自ENCODE的现有eCLIP/iCLIP数据集已与相应蛋白质相关联，同时还整合了来自R-DeeP数据库的RNA依赖性信息。两种评分——RBP2GO评分和RBP2GO综合评分——进一步支持了蛋白质的表征，这些评分反映了该蛋白质与RNA结合的概率。现在，这些评分通过针对各物种全蛋白质组的小提琴图分布进行可视化展示。重新设计的用户界面支持从主页直接对蛋白质名称、基因本体论术语、疾病本体论术语和蛋白质结构域进行直观搜索，并通过高级搜索模块提供了扩展的、多功能的搜索选项。RBP2GO 2.0是研究RBP新功能的一个宝贵工具，并可在 https://RBP2GOv2.dkfz.de 公开访问。

### 第二部分 AI 大师评价

本研究介绍了RBP2GO数据库的2.0版本，其核心目标是整合多源数据以深化对RNA结合蛋白（RBP）功能的理解。通过整合疾病本体论、新的蛋白质组学数据、序列特征可视化以及创新的RBP结合概率评分系统，该研究显著增强了数据库的实用性。此更新的创新之处在于将RBP功能与人类疾病直接关联，为探索RBP在疾病中的作用机制提供了强有力的生物信息学工具，具有重要的科研和潜在的临床转化价值。

---

## 30. CYP4X1/sEH依赖的内源性大麻素代谢驱动成纤维细胞介导的免疫抑制以限制结直肠癌的免疫治疗效果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276938](https://pubmed.ncbi.nlm.nih.gov/41276938)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41276938
**DOI：** 10.1002/advs.202507695

### 第一部分 原文与翻译

**英文原标题：** CYP4X1/sEH-Dependent Endocannabinoid Metabolism Drives Fibroblast-Mediated Immunosuppression to Limit Immunotherapy in Colon Cancer.

**英文摘要原文：**
Cytochrome P450 (CYP) 4X1 and soluble epoxide hydrolase (sEH), the key enzymes responsible for endocannabinoid oxidative metabolism, have been implicated in inflammation and cancer. However, the precise role of CYP4X1 and sEH in tumor immune evasion is poorly understood. Here, it is elucidated that CYP4X1/sEH-dependent endocannabinoid metabolism governs immune evasion in colon cancer by promoting the infiltration of regulatory T cells (Tregs) and impairing CD8 T cell effector function. Mechanistically, CYP4X1/sEH-derived 14,15-EET-EA upregulates PD-L1, CXCL12, and TGF-β in cancer-associated fibroblasts (CAFs) via the GPR119-Gs/β-arrestin 2 signaling axis. Importantly, targeted regulation of the CYP4X1/sEH-GPR119 axis enhances the efficacy of anti-PD-1 therapy. Moreover, CYP4X1 and sEH levels jointly predict prognosis and immune infiltration in human colon cancer. Together, this study highlights that CYP4X1/sEH-dependent endocannabinoid metabolism controls CAF-mediated immune evasion, and targeting the CYP4X1/sEH-14,15-EET-EA-GPR119 axis represents a promising therapeutic strategy for improving anti-PD-1 therapy in colon cancer.

**中文摘要译文：**
细胞色素P450（CYP）4X1和可溶性环氧化物水解酶（sEH）是负责内源性大麻素氧化代谢的关键酶，已被证明与炎症和癌症有关。然而，CYP4X1和sEH在肿瘤免疫逃逸中的确切作用尚不清楚。本研究阐明，CYP4X1/sEH依赖的内源性大麻素代谢通过促进调节性T细胞（Tregs）的浸润和损害CD8 T细胞的效应功能，调控结直肠癌的免疫逃逸。从机制上讲，CYP4X1/sEH衍生的14,15-EET-EA通过GPR119-Gs/β-arrestin 2信号轴，上调癌症相关成纤维细胞（CAFs）中PD-L1、CXCL12和TGF-β的表达。重要的是，对CYP4X1/sEH-GPR119轴的靶向调控可增强抗PD-1疗法的疗效。此外，CYP4X1和sEH的水平可共同预测人类结直肠癌的预后和免疫浸润情况。综上所述，本研究强调了CYP4X1/sEH依赖的内源性大麻素代谢控制着CAF介导的免疫逃逸，并且靶向CYP4X1/sEH-14,15-EET-EA-GPR119轴是提高结直肠癌抗PD-1治疗效果的一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究旨在揭示CYP4X1/sEH依赖的内源性大麻素代谢在结直肠癌免疫逃逸中的作用机制。研究发现，该代谢通路通过其产物14,15-EET-EA作用于癌症相关成纤维细胞（CAFs），上调PD-L1等免疫抑制分子的表达，从而抑制T细胞功能并促进免疫抑制。该研究的创新之处在于首次将内源性大麻素代谢、成纤维细胞与肿瘤免疫微环境联系起来，提出了靶向CYP4X1/sEH-GPR119轴作为增敏抗PD-1免疫治疗的新策略，为结直肠癌的联合治疗提供了极具价值的新靶点和理论依据。

---

## 31. 并行全基因组CRISPR筛选揭示SORL1和ZFYVE19是沙门氏菌感染的序贯性宿主决定因素

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276924](https://pubmed.ncbi.nlm.nih.gov/41276924)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41276924
**DOI：** 10.1002/advs.202515042

### 第一部分 原文与翻译

**英文原标题：** Parallel Genome-Wide CRISPR Screens Reveal SORL1 and ZFYVE19 as Sequential Host Determinants of Salmonella Infection.

**英文摘要原文：**
Salmonella enterica, a major cause of gastroenteritis and typhoid fever, hijacks host machinery to invade cells, and replicate within a specialized niche. While some host factors are known, a comprehensive, temporally-resolved understanding of the host-pathogen interface has been hindered by a lack of suitable genome-wide methodologies. To address this, a parallel CRISPR screening platform is developed to identify host determinants for distinct infection stages. An invasion screen captured factors for bacterial entry, while a fitness screen identified factors governing long-term survival. The screens reveal a temporal switch in host dependency, from endosomal trafficking in early infection to cell cycle and DNA damage response pathways governing host cell fitness in long-term infection. Notably, the approach uncovers two novel host factors with stage-specific roles, SORL1 as a mediator of bacterial invasion and ZFYVE19 as a factor supporting intracellular proliferation. Genetic disruption of SORL1 or ZFYVE19 validate these roles, leading to impaired invasion or replication, respectively. Importantly, antibody-mediated blockade of SORL1 effectively prevented Salmonella entry, highlighting it as a novel host-directed therapeutic target. Together, the screening strategy provides a powerful framework for the temporal dissection of host-pathogen interactions, revealing novel biology and promising therapeutic targets.

**中文摘要译文：**
肠道沙门氏菌是引发肠胃炎和伤寒的主要病原体，它通过劫持宿主机制入侵细胞，并在一个特化的生态位中复制。虽然部分宿主因子已被发现，但由于缺乏合适的全基因组方法学，我们对宿主-病原体相互作用界面的全面、时间分辨的理解受到了阻碍。为解决此问题，本研究开发了一个并行CRISPR筛选平台，用以鉴定不同感染阶段的宿主决定因素。入侵筛选捕获了细菌进入所需的因子，而适应性筛选则识别了调控长期存活的因子。这些筛选揭示了宿主依赖性的时间性转换：从早期感染中的内体运输，转变为长期感染中调控宿主细胞适应性的细胞周期和DNA损伤应答通路。值得注意的是，该方法发现了两个具有阶段特异性作用的新型宿主因子：SORL1作为细菌入侵的介导者，以及ZFYVE19作为支持胞内增殖的因子。对SORL1或ZFYVE19的基因敲除验证了它们的作用，分别导致了细菌入侵或复制能力的受损。重要的是，抗体介导的SORL1阻断能有效阻止沙门氏菌的进入，这凸显了其作为一个新型的宿主导向治疗靶点的潜力。总之，该筛选策略为时间维度上解析宿主-病原体相互作用提供了一个强大的框架，揭示了新的生物学机制和有前景的治疗靶点。

### 第二部分 AI 大师评价

本研究利用创新的并行全基因组CRISPR筛选平台，旨在系统性地、分阶段地鉴定沙门氏菌感染过程中的关键宿主决定因素。该研究不仅成功揭示了感染早期（入侵阶段）和长期（增殖阶段）宿主依赖性的动态转换，还首次发现了SORL1和ZFYVE19分别在入侵和胞内增殖中的特异性作用。此方法论为动态解析宿主-病原体相互作用提供了强有力的范式，并将SORL1确立为一个极具潜力的宿主导向抗感染治疗新靶点，具有重要的科研和临床转化价值。

---

## 32. 双金属过氧化物纳米复合材料驱动的氧化还原失衡以激活序贯性铜死亡和焦亡从而增强肿瘤免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276916](https://pubmed.ncbi.nlm.nih.gov/41276916)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41276916
**DOI：** 10.1002/advs.202512470

### 第一部分 原文与翻译

**英文原标题：** Bimetallic Peroxide Nanocomposites-Driven Redox Dyshomeostasis to Activate Sequential Cuproptosis and Pyroptosis for Amplified Tumor Immunotherapy.

**英文摘要原文：**
Although metal peroxides are extensively employed in tumor therapy, novel synergistic tumor treatment approaches based on the combination of multiple types of metal peroxides are still lacking and warrant further exploration. To overcome this challenge, hyaluronic acid (HA)-modified bimetallic peroxide nanocomposites (MgO-CuO@HA NCs) are developed by combining magnesium peroxide (MgO) nanosheets and short-grained copper peroxide (CuO) nanodots. By modifying HA to enhance tumor targeting and stability, MgO-CuO@HA NCs leverage pH-dependent decomposition to release Mg, HO, and Cu under acidic conditions, thereby initiating Fenton-like reactions for the generation of hydroxyl radicals (•OH), while simultaneously depleting glutathione to generate Cu. This process induces cuproptosis through the Cu-mediated oligoaggregation of dihydrolipoamide S-acetyltransferase. Additionally, enhanced •OH activates pyroptosis via the caspase-1/gasdermin D pathway. Cuproptosis and pyroptosis can induce immunogenic cell death, thereby triggering the anti-tumor immune responses. Notably, released Mg can enhance the activation of CD8 T cells by promoting the conformational activation of leukocyte function-associated antigen 1. Therefore, this study establishes a novel paradigm for synergistic anti-tumor immunotherapy based on bimetallic peroxide nanocomposites, offering promising prospects for clinical immunotherapy.

**中文摘要译文：**
尽管金属过氧化物在肿瘤治疗中被广泛应用，但基于多种金属过氧化物组合的新型协同肿瘤治疗方法仍然缺乏，有待进一步探索。为应对这一挑战，本研究通过结合过氧化镁（MgO）纳米片和短粒状过氧化铜（CuO）纳米点，开发了透明质酸（HA）修饰的双金属过氧化物纳米复合材料（MgO-CuO@HA NCs）。通过修饰透明质酸以增强肿瘤靶向性和稳定性，MgO-CuO@HA NCs利用pH依赖性分解，在酸性条件下释放Mg²⁺、H₂O₂和Cu²⁺，从而引发芬顿样反应生成羟基自由基（•OH），同时消耗谷胱甘肽生成Cu⁺。该过程通过Cu⁺介导的二氢硫辛酰胺S-乙酰转移酶的寡聚化诱导铜死亡。此外，增强的•OH通过caspase-1/gasdermin D通路激活焦亡。铜死亡和焦亡可诱导免疫原性细胞死亡，从而触发抗肿瘤免疫反应。值得注意的是，释放的Mg²⁺可以通过促进白细胞功能相关抗原1的构象激活来增强CD8⁺ T细胞的活化。因此，本研究建立了一种基于双金属过氧化物纳米复合材料的协同抗肿瘤免疫治疗新范式，为临床免疫治疗提供了广阔的前景。

### 第二部分 AI 大师评价

本研究旨在开发一种新型双金属过氧化物纳米复合材料，以实现协同抗肿瘤免疫治疗。研究人员巧妙地将过氧化镁与过氧化铜结合，并利用透明质酸进行修饰，构建了能够在肿瘤酸性微环境下响应性释放活性物质的纳米平台。该平台的关键发现是能够通过诱导氧化还原失衡，序贯性地激活铜死亡和细胞焦亡两种细胞死亡通路，并利用释放的镁离子增强T细胞的免疫功能。这项工作通过一种材料同时启动“细胞杀伤”和“免疫激活”双重机制，为开发高效的肿瘤免疫疗法提供了创新的策略和极具潜力的临床应用前景。

---

## 33. 巨噬细胞硬骨素Loop2-ApoER2的相互作用是硬骨素发挥心血管保护作用所必需的

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276911](https://pubmed.ncbi.nlm.nih.gov/41276911)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41276911
**DOI：** 10.1002/advs.202518735

### 第一部分 原文与翻译

**英文原标题：** Macrophagic Sclerostin Loop2-ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action.

**英文摘要原文：**
Therapeutic antibody against sclerostin loop2 promoted bone formation in postmenopausal osteoporosis but caused severe cardiovascular events in clinical applications. The studies of atherosclerosis and aortic aneurysm in SOST.ApoE mice and sost.ApoE mice collectively indicated the cardiovascular protective action of sclerostin. However, how sclerostin exerts cardiovascular protective action remains unclear. In this study, ApoER2 (LRP8) is notably identified as a novel transmembrane receptor for sclerostin in macrophages. Mechanistically, blockade of macrophagic sclerostin loop2-ApoER2 interaction attenuates the suppressive effects of sclerostin on NF-κB nuclear translocation, phosphorylation, and mRNA expression in macrophages, reduces the promotive effects of sclerostin on macrophage conversion to anti-inflammatory phenotypes, and inhibits the preventive effects of sclerostin on atherosclerosis and aortic aneurysm in ApoE mice. Together, macrophagic sclerostin loop2-ApoER2 interaction is required by sclerostin to suppress inflammatory responses, atherosclerosis, and aortic aneurysm in ApoE mice. Sclerostin plays a compensatory protective role in the cardiovascular system when ApoE is absent or mutated. Translationally, it provided critical pre-clinical evidence regarding the prediction of cardiovascular risk populations (e.g., APOE variants) for the marketed antibody against sclerostin loop2. Importantly, targeting sclerostin while preserving macrophagic sclerostin loop2-ApoER2 interaction would offer the next generation of precise sclerostin inhibition strategy without cardiovascular safety concern, while promoting bone formation.

**中文摘要译文：**
针对硬骨素loop2的治疗性抗体在促进绝经后骨质疏松症患者骨形成的同时，在临床应用中却引发了严重的心血管事件。对SOST.ApoE小鼠和sost.ApoE小鼠的动脉粥样硬化和主动脉瘤的研究共同表明，硬骨素具有心血管保护作用。然而，硬骨素如何发挥其心血管保护作用尚不清楚。在本研究中，ApoER2 (LRP8) 被鉴定为巨噬细胞上硬骨素的一个新型跨膜受体。从机制上讲，在ApoE小鼠中，阻断巨噬细胞的硬骨素loop2-ApoER2相互作用，会减弱硬骨素对巨噬细胞中NF-κB核转位、磷酸化和mRNA表达的抑制作用，降低硬骨素促进巨噬细胞向抗炎表型转化的作用，并抑制硬骨素对动脉粥样硬化和主动脉瘤的预防效果。综上所述，在ApoE小鼠中，硬骨素需要通过巨噬细胞的硬骨素loop2-ApoER2相互作用来抑制炎症反应、动脉粥样硬化和主动脉瘤。当ApoE缺失或发生突变时，硬骨素在心血管系统中发挥代偿性的保护作用。在转化医学方面，本研究为预测已上市的抗硬骨素loop2抗体的（应用人群中的）心血管风险人群（例如，APOE变异携带者）提供了关键的临床前证据。重要的是，在靶向硬骨素的同时保留巨噬细胞的硬骨素loop2-ApoER2相互作用，将为下一代精准硬骨素抑制策略提供新思路，该策略能在促进骨形成的同时，没有心血管安全性方面的顾虑。

### 第二部分 AI 大师评价

本研究旨在阐明硬骨素发挥心血管保护作用的分子机制，以解释抗硬骨素抗体在临床上引发心血管不良事件的原因。研究通过小鼠模型和细胞实验，创新性地发现巨噬细胞上的ApoER2是硬骨素的新型受体，并证实硬骨素loop2与ApoER2的相互作用是抑制炎症、预防动脉粥样硬化和主动脉瘤的关键。这一发现不仅为评估现有疗法的心血管风险提供了临床前证据（如APOE变异人群），更重要的是，为开发既能促进骨形成又无心血管安全隐患的新一代精准硬骨素抑制剂指明了新方向，具有重大的临床转化价值。

---

## 34. 鉴定PKN2和MOB4为集体细胞迁移的协调因子

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276909](https://pubmed.ncbi.nlm.nih.gov/41276909)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41276909
**DOI：** 10.1002/advs.202502907

### 第一部分 原文与翻译

**英文原标题：** Identification of PKN2 and MOB4 as Coordinators of Collective Cell Migration.

**英文摘要原文：**
In animals, collective cell migration is critical during development and adult life for repairing organs. It remains, however, poorly understood compared with single-cell migration. The polymerization of branched actin by the RAC1-WAVE-Arp2/3 pathway is established to power membrane protrusions at the front of migrating cells, but also to maintain cell junctions in epithelial monolayers. Here, novel regulators of collective cell migration are identified using a two-pronged approach: candidates are extracted from publicly available RAC1-WAVE-Arp2/3 dependency maps and screened in a second step using CRISPR/Cas9 genetic inactivation. In a wound healing assay, PKN2 knockout (KO) MCF10A cells display decreased collective migration due to destabilization of adherens junctions, whereas MOB4 KO cells display increased collective migration with a loss of migration orientation. Upon wound healing, PKN2 relocalizes to lateral junctions and maintains coordinated migration in the monolayer, whereas MOB4 relocalizes to the front edge of leader and follower cells collectively migrating toward the wound. The role of MOB4 in controlling collective migration requires YAP1, since MOB4 KO cells fail to activate YAP1, and their phenotype is rescued by constitutively active YAP1. Together, these findings reveal two complementary activities required for coordinating cells in collective migration.

**中文摘要译文：**
在动物体内，集体细胞迁移在发育过程和成年期器官修复中至关重要。然而，与单细胞迁移相比，我们对集体细胞迁移的理解仍然非常有限。RAC1-WAVE-Arp2/3通路介导的分支肌动蛋白聚合已被证实可驱动迁移细胞前端的膜突起，并维持上皮单层细胞间的连接。本研究采用一种双管齐下的方法来鉴定集体细胞迁移的新型调控因子：首先从公开的RAC1-WAVE-Arp2/3依赖性图谱中提取候选分子，然后利用CRISPR/Cas9基因失活技术进行第二步筛选。在伤口愈合实验中，PKN2敲除（KO）的MCF10A细胞因粘附连接失稳而表现出集体迁移能力下降，而MOB4敲除的细胞则表现出集体迁移能力增强但丧失了迁移方向性。在伤口愈合过程中，PKN2重新定位到细胞侧向连接处，维持细胞单层的协同迁移；而MOB4则重新定位到朝向伤口进行集体迁移的领导细胞和跟随细胞的前缘。MOB4在控制集体迁移中的作用需要YAP1的参与，因为MOB4敲除的细胞无法激活YAP1，并且其表型可以通过持续激活的YAP1得以挽救。总之，这些发现揭示了在集体细胞迁移中协调细胞所需的两种互补性活动。

### 第二部分 AI 大师评价

本研究采用生物信息学筛选结合CRISPR/Cas9基因编辑的双重策略，旨在发现调控集体细胞迁移的新型关键因子。研究成功鉴定出PKN2和MOB4两个蛋白，并揭示了它们的互补作用机制：PKN2通过稳定粘附连接来维持迁移的协调性，而MOB4则通过YAP1通路确保细胞迁移的方向性。这项工作不仅为理解集体细胞迁移的复杂调控网络提供了新的分子靶点，也为探索伤口愈合、器官发育及肿瘤转移等相关病生理过程的干预策略开辟了新思路，具有重要的科研价值。

---

## 35. 肿瘤干细胞通过转移代谢物乙酰辅酶A来阻断CD103+ T细胞的分化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276906](https://pubmed.ncbi.nlm.nih.gov/41276906)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41276906
**DOI：** 10.1002/advs.202513535

### 第一部分 原文与翻译

**英文原标题：** Cancer Stem Cells Shift Metabolite Acetyl-Coenzyme A to Abrogate the Differentiation of CD103 T Cells.

**英文摘要原文：**
CD103 T cells mediate potent anti-tumor immune responses and correlate with favorable clinical outcomes in cancer patients. However, the mechanisms by which cancer cells influence the differentiation of these cells remain elusive. Herein, we demonstrate that cancer stem cells (CSCs) play a pivotal role in suppressing CD103 T cell differentiation in patients with non-small cell lung cancer (NSCLC). Specifically, CSCs facilitate the transfer of the metabolite acetyl-coenzyme A (acetyl-CoA) into interacting T cells via an exosome-dependent pathway. This process enhances the acetylation of B lymphocyte-induced maturation protein 1 (Blimp-1), a critical transcription factor governing CD103 T cell differentiation. Acetylation of Blimp-1 strengthens its interaction with the E3 ubiquitin ligase LIS1, thereby promoting Blimp-1 degradation, which ultimately blocks CD103 T cell differentiation. Accordingly, targeting CSCs and acetyl-CoA biosynthesis using CD133 antibody-conjugated nanoparticles increases tumor-infiltrating CD8CD103 T cells and suppresses tumor growth. Importantly, studies using NSCLC patient-derived organoids (PDOs) and humanized PDO-NSG chimeras confirmed that blocking acetyl-CoA production, exosome secretion from CSCs, and key enzymes involved in Blimp-1 acetylation and ubiquitination effectively restores CD103 T cell differentiation. Altogether, CSC acetyl-CoA is a key contributor in impairing CD103 T cells through programming post-translational modifications, serving as a promising therapeutic target in anti-tumor therapy.

**中文摘要译文：**
CD103+ T细胞介导了强有力的抗肿瘤免疫反应，并与癌症患者的良好临床预后相关。然而，肿瘤细胞影响此类细胞分化的具体机制尚不明确。在本研究中，我们证明了肿瘤干细胞（CSCs）在抑制非小细胞肺癌（NSCLC）患者的CD103+ T细胞分化中起着关键作用。具体而言，CSCs通过外泌体依赖性途径，促进代谢物乙酰辅酶A（acetyl-CoA）转移至相互作用的T细胞中。这一过程增强了B淋巴细胞诱导成熟蛋白1（Blimp-1）的乙酰化，而Blimp-1是调控CD103+ T细胞分化的一个关键转录因子。Blimp-1的乙酰化加强了其与E3泛素连接酶LIS1的相互作用，从而促进Blimp-1的降解，最终阻断了CD103+ T细胞的分化。相应地，使用CD133抗体偶联的纳米颗粒靶向CSCs和乙酰辅酶A的生物合成，能够增加肿瘤浸润性CD8+CD103+ T细胞的数量并抑制肿瘤生长。重要的是，利用NSCLC患者来源的类器官（PDOs）和人源化的PDO-NSG嵌合体模型进行的研究证实，阻断乙酰辅酶A的产生、CSCs的外泌体分泌，以及参与Blimp-1乙酰化和泛素化的关键酶，可以有效恢复CD103+ T细胞的分化。总而言之，来自CSC的乙酰辅酶A通过调控翻译后修饰，成为损害CD103+ T细胞功能的关键因素，并可作为抗肿瘤治疗中一个有前景的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在揭示肿瘤干细胞（CSCs）抑制抗肿瘤CD103+ T细胞分化的深层机制。研究团队创新性地发现，在非小细胞肺癌中，CSCs通过外泌体将代谢物乙酰辅酶A转移给T细胞，进而诱导关键转录因子Blimp-1的乙酰化与降解，最终阻断了CD103+ T细胞的分化。这一发现不仅揭示了肿瘤通过代谢重编程进行免疫逃逸的新途径，更重要的是，它指出了靶向CSCs的乙酰辅酶A生物合成或其转移通路，有望成为恢复抗肿瘤免疫、提升治疗效果的全新策略，具有重要的临床转化潜力。

---

## 36. 儿科危重症两年后，昼夜节律同步和时钟基因的异常DNA甲基化与身体和神经认知发育受损相关

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276843](https://pubmed.ncbi.nlm.nih.gov/41276843)
**期刊：** Clinical epigenetics
**PMID：** 41276843
**DOI：** 10.1186/s13148-025-02027-3

### 第一部分 原文与翻译

**英文原标题：** Aberrant DNA methylation within circadian entrainment and clock genes two years after pediatric critical illness is associated with impaired physical and neurocognitive development.

**英文摘要原文：**
BACKGROUND: Pediatric critical illness can disrupt circadian rhythms, potentially leading to long-term deficits in growth, neurocognition, and behavior. Disturbances in circadian rhythms have been associated with altered gene expression and DNA methylation. We investigated long-term DNA methylation alterations in circadian entrainment and clock genes in children previously admitted to the pediatric intensive care unit (PICU), the influence of parenteral nutrition (PN) timing hereon and their associations with long-term health outcomes.

METHODS: This study is a secondary analysis of the PEPaNIC randomized controlled trial (RCT) and its two-year follow-up. The PEPaNIC-RCT randomized critically ill children to early initiation of supplemental PN within the first 24 h or its omission in the first week of PICU admission. DNA methylation of 127 circadian entrainment and clock genes was studied in buccal mucosa DNA of former PICU patients (n = 818) and matched healthy children (n = 392) at the two-year follow-up using Infinium® HumanMethylation EPIC BeadChips. Multivariable linear models were used to identify differential methylation between former patients and controls and their association with randomization group and outcomes at two-year follow-up.

RESULTS: Former PICU patients showed 61 differentially methylated CpG sites (DMPs) within 34 of the genes, with 60 (98.4%) showing hypomethylation as compared with healthy children. Omitting early PN during PICU stay did not affect CpG site methylation. 702 associations (34.9%) were observed between abnormal DNA methylation and adverse long-term health and developmental outcomes, most notably visual-motor integration (47 DMPs, 77%), height (46 DMPs, 75%) and total IQ (46 DMPs, 75%).

CONCLUSION: Former PICU patients exhibited altered DNA methylation in circadian entrainment and clock genes compared to healthy children, and this was associated with impaired growth, neurocognition and behavioral problems at two-year follow-up. Disruptions in circadian entrainment and clock gene methylation may contribute to the adverse long-term health consequences that children experience after critical illness.

**中文摘要译文：**
背景：儿科危重症可扰乱昼夜节律，可能导致生长、神经认知和行为的长期缺陷。昼夜节律的紊乱与基因表达和DNA甲基化的改变有关。我们研究了既往入住儿科重症监护室（PICU）的儿童中，昼夜节律同步和时钟基因的长期DNA甲基化改变、肠外营养（PN）时机对此的影响，以及这些改变与长期健康结局的关联。

方法：本研究是对PEPaNIC随机对照试验（RCT）及其两年随访数据的二次分析。PEPaNIC-RCT将危重症患儿随机分为在入住PICU的最初24小时内早期开始补充性PN，或在第一周内不使用PN。在为期两年的随访中，我们使用Infinium® HumanMethylation EPIC BeadChips技术，研究了既往PICU患儿（n = 818）和匹配的健康儿童（n = 392）颊黏膜DNA中127个昼夜节律同步和时钟基因的DNA甲基化情况。采用多变量线性模型来确定既往患儿与对照组之间的差异甲基化，及其与随机分组和两年随访结局的关联。

结果：与健康儿童相比，既往PICU患儿在34个基因中显示出61个差异甲基化CpG位点（DMPs），其中60个（98.4%）表现为低甲基化。在PICU住院期间不使用早期PN对CpG位点的甲基化没有影响。观察到异常DNA甲基化与不良的长期健康和发育结局之间存在702个关联（34.9%），其中最显著的是与视觉-运动整合能力（47个DMPs, 77%）、身高（46个DMPs, 75%）和总智商（46个DMPs, 75%）的关联。

结论：与健康儿童相比，既往PICU患儿的昼夜节律同步和时钟基因表现出DNA甲基化改变，这与两年随访时的生长受损、神经认知及行为问题相关。昼夜节律同步和时钟基因甲基化的紊乱可能是导致儿童在危重症后经历长期不良健康后果的原因之一。

### 第二部分 AI 大师评价

本研究旨在探讨儿科危重症对患儿昼夜节律相关基因DNA甲基化的长期影响，并阐明其与两年后身体及神经认知发育结局的关联。该研究基于一项大型随机对照试验的随访数据，通过对比患儿与健康儿童的表观遗传学差异，发现重症经历会导致昼夜节律基因的持续性低甲基化，并与身高、智商及视动整合能力等发育指标受损显著相关。此项工作的创新之处在于从表观遗传学层面揭示了儿科危重症长期后遗症的潜在生物学机制，为理解和干预“重症后综合征”提供了新的分子靶点和研究方向。

---

## 37. GSTK1通过PGAM5/DRP1复合物介导的线粒体质量控制调控L-肉碱代谢，从而抑制肝细胞癌的恶化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276823](https://pubmed.ncbi.nlm.nih.gov/41276823)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41276823
**DOI：** 10.1186/s13046-025-03580-8

### 第一部分 原文与翻译

**英文原标题：** GSTK1 suppresses HCC aggravation via L-carnitine metabolism by PGAM5/DRP1 complex-mediated mitochondrial quality control.

**英文摘要原文：**
BACKGROUND: Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related mortality worldwide. The high recurrence rate and resistance to chemotherapy of HCC contribute to poor clinical outcomes, necessitating the development of novel therapeutic strategies. Glutathione S-transferase kappa 1 (GSTK1) is specifically localized to mitochondria and peroxisomes, participates in adiponectin secretion and insulin resistance, and inhibits the progression of non-alcoholic fatty liver disease. However, the role of GSTK1 in HCC is unknown. We aimed to determine the role of GSTK1 in HCC progression.

METHODS: N-nitrosodiethylamine (DEN)/ carbon tetrachloride and DEN/high-fat, high-fructose, high-cholesterol diet models were used in hepatocyte-specific Gstk1 knockout and control mice to establish a murine HCC model. Human HCC cell lines with GSTK1 overexpression or knockdown were used to determine GSTK1 function in tumor growth and migration in vitro. Non-target metabolomics analysis, RNA-sequence, transmission electron microscope (TEM), immunoprecipitation (IP), liquid chromatography, and high-throughput mass spectrometry (LC-MS/MS) were used to determine the mechanism by which GSTK1 participates in HCC.

RESULTS: GSTK1 was shown to suppress HCC in vivo and in vitro. Non-target metabolomics analysis indicated that GSTK1 participates in L-carnitine metabolism. L-carnitine supplementation inhibited proliferation and promoted apoptosis of HCC cells in vivo and in vitro. This effect was enhanced by GSTK1 overexpression. Mechanically, TEM and western blot showed that GSTK1 influences mitochondrial quality control (MQC) by promoting mitochondrial biosynthesis and mitochondrial fusion. GSTK1 was shown to inhibit mitochondrial fission and mitophagy, which was consistent with the immunofluorescence results. IP and LC-MS/LMS indicated that GSTK1 combines with PGAM5 and competes with DRP1. Additionally, GSTK1 was shown to be regulated by transcription factors (PPARα/RXRα) and the RXRα agonist, bexarotene, inhibited HCC cell proliferation.

CONCLUSIONS: GSTK1 was shown to be a tumor suppressor via its role in MQC and L-carnitine metabolism. Bexarotene and L-carnitine supplementation may serve as potential therapeutic strategies for HCC treatment.

**中文摘要译文：**
背景: 肝细胞癌（HCC）是全球范围内癌症相关死亡的主要原因之一。HCC的高复发率和化疗耐药性导致其临床预后不佳，因此亟需开发新的治疗策略。谷胱甘肽S-转移酶kappa 1（GSTK1）特异性定位于线粒体和过氧化物酶体，参与脂联素分泌和胰岛素抵抗，并抑制非酒精性脂肪性肝病的进展。然而，GSTK1在HCC中的作用尚不明确。我们旨在阐明GSTK1在HCC进展中的作用。

方法: 我们在肝细胞特异性Gstk1敲除小鼠和对照小鼠中，使用N-亚硝基二乙胺（DEN）/四氯化碳和DEN/高脂、高果糖、高胆固醇饮食模型来建立小鼠HCC模型。我们利用过表达或敲低GSTK1的人HCC细胞系，在体外研究GSTK1在肿瘤生长和迁移中的功能。我们采用非靶向代谢组学分析、RNA测序、透射电子显微镜（TEM）、免疫沉淀（IP）、液相色谱和高通量质谱（LC-MS/MS）等技术来探究GSTK1参与HCC的分子机制。

结果: 研究表明，GSTK1在体内和体外均能抑制HCC。非靶向代谢组学分析表明，GSTK1参与L-肉碱代谢。补充L-肉碱在体内和体外均能抑制HCC细胞的增殖并促进其凋亡。GSTK1的过表达增强了这一效应。机制上，TEM和蛋白质印迹法结果显示，GSTK1通过促进线粒体生物合成和线粒体融合来影响线粒体质量控制（MQC）。研究发现GSTK1抑制线粒体分裂和线粒体自噬，这与免疫荧光结果一致。IP和LC-MS/MS结果表明，GSTK1与PGAM5结合，并与DRP1竞争。此外，研究还发现GSTK1受转录因子（PPARα/RXRα）的调控，并且RXRα激动剂贝沙罗汀能抑制HCC细胞的增殖。

结论: GSTK1通过其在线粒体质量控制和L-肉碱代谢中的作用，被证实是一种肿瘤抑制因子。贝沙罗汀和补充L-肉碱可能成为治疗HCC的潜在策略。

### 第二部分 AI 大师评价

本研究旨在揭示线粒体蛋白GSTK1在肝细胞癌（HCC）进展中的作用及其分子机制。研究综合运用了基因编辑小鼠模型、细胞功能实验及多组学分析等手段，关键性地发现GSTK1通过调控L-肉碱代谢及PGAM5/DRP1复合物介导的线粒体质量控制，从而发挥抑癌功能。此项工作的创新之处在于首次将GSTK1与HCC的代谢重编程和线粒体动态平衡直接关联，不仅深化了对HCC发病机制的理解，还提出了补充L-肉碱和使用贝沙罗汀作为潜在的治疗新策略，具有重要的科研和临床转化价值。

---

## 38. 二甲双胍的慢性给药通过抑制胶质母细胞瘤起始细胞中的tmCLIC1膜蛋白，经由PP2A-GSK3β-MCL-1通路发挥细胞生长抑制和细胞毒性作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276810](https://pubmed.ncbi.nlm.nih.gov/41276810)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41276810
**DOI：** 10.1186/s13046-025-03577-3

### 第一部分 原文与翻译

**英文原标题：** Chronic administration of metformin exerts cytostatic and cytotoxic effects via the PP2A-GSK3β-MCL-1 pathway by inhibiting the tmCLIC1 membrane protein in glioblastoma-initiating cells.

**英文摘要原文：**
BACKGROUND: One of the main challenges in cancer treatment is addressing the metabolic reprogramming of tumor cells, which require more energy and biomolecules than healthy cells. Cancer cells alter their metabolism by switching between glycolysis and oxidative phosphorylation (OXPHOS). These processes depend on transmembrane proteins that respond to the extracellular environment. Our research identified the transmembrane form of Chloride Intracellular Channel 1 (tmCLIC1) as a marker of malignancy and a potential therapeutic target. tmCLIC1 levels are increased in several solid tumors, supporting cancer growth and progression, whereas they are mostly absent in healthy cells. We confirmed that tmCLIC1 is the specific target of the antidiabetic drug metformin, an OXPHOS inhibitor in cancer cells.

METHODS: tmCLIC1 is the primary target of metformin in glioblastoma-initiating cells, as shown by single-channel patch-clamp recordings and NMR experiments. Various patient-derived glioblastoma cells with different genetic backgrounds were used to demonstrate that CLIC1 CRISPR-Cas9 knockout and/or its point mutation at arginine 29 removes metformin's antitumor effects. Functional assays were used to assess the effects on proliferation, mitochondrial metabolism, and tumor growth in vitro and in vivo, using zebrafish and murine xenograft models.

RESULTS: Metformin inhibits the function of tmCLIC1 through direct and specific binding involving arginine 29 in the tmCLIC1 sequence. Additionally, during hypoglycemia, metformin promotes glioblastoma cell apoptosis by inhibiting the Cancerous Inhibitor of Protein Phosphatase 2 A (CIP2A) and activating the PP2A B56δ subunit. This leads to the dephosphorylation of Glycogen Synthase Kinase 3 Beta (GSK3β), resulting in the breakdown of the pro-survival protein MCL-1 and subsequent cell death. Inhibition of tmCLIC1 is crucial for this metformin-driven antineoplastic effect, mainly through regulating the PP2A-GSK3β-MCL-1 pathway under hypoglycemic conditions. The chronic presence of metformin within the tumors impairs in vivo growth at nanomolar concentrations.

CONCLUSIONS: The therapeutic role of metformin to treat brain tumors remains debated. Our findings show that drug delivery is essential, as in vivo, tumor growth decreases at concentrations below 10 nanomolar. We propose that sustained CNS metformin levels may improve tmCLIC1 inhibition, providing a basis for optimizing interactions with metformin or related compounds to enhance therapeutic efficacy.

**中文摘要译文：**
背景：癌症治疗的主要挑战之一是解决肿瘤细胞的代谢重编程问题，因为肿瘤细胞比健康细胞需要更多的能量和生物分子。癌细胞通过在糖酵解和氧化磷酸化（OXPHOS）之间切换来改变其新陈代谢。这些过程依赖于响应细胞外环境的跨膜蛋白。我们的研究将氯离子细胞内通道蛋白1的跨膜形式（tmCLIC1）鉴定为一种恶性标志物和潜在的治疗靶点。tmCLIC1在多种实体瘤中水平升高，支持癌症的生长和进展，而在健康细胞中则基本不存在。我们证实，tmCLIC1是抗糖尿病药物二甲双胍（一种癌细胞中的OXPHOS抑制剂）的特异性靶点。

方法：通过单通道膜片钳记录和核磁共振实验表明，tmCLIC1是二甲双胍在胶质母细胞瘤起始细胞中的主要靶点。我们使用了多种具有不同遗传背景的患者来源的胶质母细胞瘤细胞，证明通过CRISPR-Cas9技术敲除CLIC1和/或其精氨酸29位点突变，可以消除二甲双胍的抗肿瘤作用。我们利用斑马鱼和鼠源异种移植模型，通过功能性实验评估了二甲双胍在体外和体内对细胞增殖、线粒体代谢以及肿瘤生长的影响。

结果：二甲双胍通过与tmCLIC1序列中的精氨酸29发生直接且特异性的结合，从而抑制tmCLIC1的功能。此外，在低糖条件下，二甲双胍通过抑制蛋白磷酸酶2A的癌性抑制因子（CIP2A）并激活PP2A B56δ亚基，促进胶质母细胞瘤细胞凋亡。这导致糖原合成酶激酶3β（GSK3β）去磷酸化，进而促使促生存蛋白MCL-1分解，最终导致细胞死亡。抑制tmCLIC1对于二甲双胍驱动的这种抗肿瘤效应至关重要，主要是在低糖条件下通过调节PP2A-GSK3β-MCL-1通路实现。肿瘤内二甲双胍的慢性存在，即使在纳摩尔浓度下也能抑制体内肿瘤的生长。

结论：二甲双胍治疗脑肿瘤的疗效仍有争议。我们的研究结果表明，药物递送至关重要，因为在体内，当浓度低于10纳摩尔时，肿瘤生长即会减缓。我们认为，维持中枢神经系统内二甲双胍的持续水平可以改善对tmCLIC1的抑制效果，这为优化与二甲双胍或相关化合物的相互作用以提高治疗效果提供了基础。

### 第二部分 AI 大师评价

本研究精准揭示了抗糖药物二甲双胍在胶质母细胞瘤治疗中的一个全新分子机制，其核心创新在于首次证实了跨膜氯离子通道蛋白1（tmCLIC1）是二甲双胍的直接作用靶点。研究通过基因编辑、细胞功能实验及动物模型，清晰阐述了二甲双胍如何通过靶向tmCLIC1来调控PP2A-GSK3β-MCL-1信号通路，最终诱导肿瘤细胞凋亡。该发现不仅为二甲双胍治疗脑瘤的争议提供了关键的分子证据，更强调了持续低浓度给药的临床转化价值，为开发靶向tmCLIC1的新型抗癌策略开辟了道路。

---

## 39. 利用X射线3D虚拟组织学技术重新审视滤泡性甲状腺癌复发病例

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276719](https://pubmed.ncbi.nlm.nih.gov/41276719)
**期刊：** Endocrine pathology
**PMID：** 41276719
**DOI：** 10.1007/s12022-025-09891-y

### 第一部分 原文与翻译

**英文原标题：** Follicular Thyroid Carcinoma Relapse Cases - Revisited by X-ray 3D Virtual Histology.

**英文摘要原文：**
The diagnosis and prognosis of follicular thyroid neoplasms are based on the identification of capsular and vascular invasion. Although conventional histology allows accurate classification in most cases, its inherent limitations in tissue sampling can result in misjudgment of both the presence and extent of invasion, and occasionally result in diagnostic inaccuracies. Consequently, unexpected tumor recurrence or overtreatment still represent significant clinical challenges. To mitigate these limitations, emerging diagnostic approaches are exploring advanced imaging modalities. X-ray 3D virtual histology has been reported to enable non-destructive and comprehensive sampling of the entire tumor volume embedded in formalin-fixed paraffin-embedded blocks. In thisstudy, the X-ray 3D virtual histology technique is first evaluated by classifying 99 follicular thyroid carcinomas and 31 follicular adenomas, achieving an accuracy of 89.2%. It is then applied to tissue blocks from five relapse cases that were postoperatively diagnosed as adenomas using conventional histology. Three of five tumors exhibited at least one unequivocal focus of vascular invasion, reinforcing that even a single well-defined focus portends significant risk of recurrence and distant metastasis. Although histological confirmation at this stage remained necessary, X-ray 3D virtual histology proved to be a valuable screening method.

**中文摘要译文：**
滤泡性甲状腺肿瘤的诊断与预后建立在对包膜和血管侵犯的识别之上。尽管传统组织学在多数情况下能实现准确定性，但其固有的组织取样局限性可能导致对侵犯存在与否及其范围的误判，并偶尔引致诊断不准确。因此，非预期的肿瘤复发或过度治疗仍然是重大的临床挑战。为缓解这些局限，新兴的诊断方法正在探索先进的成像模式。据报道，X射线3D虚拟组织学技术能够对包埋于福尔马林固定石蜡包埋块中的整个肿瘤体积进行无损、全面的取样。在本研究中，首先通过对99例滤泡性甲状腺癌和31例滤泡性腺瘤进行分类，评估了X射线3D虚拟组织学技术，其准确率达到了89.2%。随后，该技术被应用于五个复发病例的组织块，这些病例在术后通过传统组织学被诊断为腺瘤。结果发现，五个肿瘤中有三个表现出至少一个明确的血管侵犯灶，这再次证实了即使是单个明确的侵犯灶也预示着显著的复发和远处转移风险。尽管在此阶段组织学确认仍是必要的，但X射线3D虚拟组织学被证明是一种有价值的筛查方法。

### 第二部分 AI 大师评价

本研究旨在评估X射线3D虚拟组织学技术在滤泡性甲状腺肿瘤诊断中的应用价值，特别是针对那些初诊为良性但后续复发的疑难病例。研究通过对已知良恶性病例进行分类验证了该技术的准确性，并成功在5例初诊为腺瘤的复发病例中发现了3例存在传统方法遗漏的血管侵犯。这一发现凸显了该技术作为一种无损、全样本筛查工具的创新性，它能有效弥补传统组织学取样的局限性，在鉴别诊断和预测复发风险方面具有重要的临床潜力，有助于避免漏诊和不必要的过度治疗。

---

## 40. 一种选择性RPL15 PROTAC降解剂在鼠黑色素瘤肿瘤模型中增强抗PD-1免疫治疗效果。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276688](https://pubmed.ncbi.nlm.nih.gov/41276688)
**期刊：** Oncogene
**PMID：** 41276688
**DOI：** 10.1038/s41388-025-03641-4

### 第一部分 原文与翻译

**英文原标题：** A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model.

**英文摘要原文：**
Damage-associated molecular patterns (DAMPs) are secreted from damaged or dying cells and activate innate immune signaling via pattern-recognition receptors such as Toll-like receptors and cGAS. We previously showed that topotecan, a chemotherapeutic drug and topoisomerase I (TOP1) inhibitor, binds to ribosomal protein RPL15 and induces the secretion of DAMPs from cancer cells, which activate cGAS-STING signaling in dendritic cells. RPL15-knockdown B16-F10 melanoma tumors were sensitized to anti-PD-1 antibody, suggesting that RPL15 inhibition may have the potential to improve immune checkpoint inhibitor efficacy. However, topotecan and its derivatives, including SN-38, are highly cytotoxic because of their TOP1 inhibitory activity. Here, we synthesized SN-38-conjugated pomalidomide (SN38-PROTAC) and showed that SN38-PROTAC induced ubiquitin-mediated degradation of RPL15, but not TOP1. SN38-PROTAC treatment induced DAMP secretion from cancer cells, which activated cGAS-STING signaling in dendritic cells. The cytotoxicity of SN38-PROTAC in MCF7 cells was 100-fold lower than SN-38. SN38-PROTAC treatment increased the CTL/Treg ratio in tumors and sensitized B16-F10 tumors to anti-PD-1 antibody in a mouse model. The enhanced antitumor effects of SN38-PROTAC and anti-PD-1 antibody combination were abolished in STING-deficient mice. Our results indicate that SN38-PROTAC, which induces RPL15 degradation, has the potential to enhance ICI efficacy in PD-1-resistant cancer with low cytotoxicity.

**中文摘要译文：**
损伤相关分子模式 (DAMPs) 由受损或濒死细胞分泌，通过Toll样受体和cGAS等模式识别受体激活先天性免疫信号。我们先前的研究表明，化疗药物及拓扑异构酶I (TOP1) 抑制剂拓扑替康，能与核糖体蛋白RPL15结合并诱导癌细胞分泌DAMPs，从而激活树突状细胞中的cGAS-STING信号通路。敲低RPL15的B16-F10黑色素瘤对PD-1抗体治疗敏感，这表明抑制RPL15可能具有提高免疫检查点抑制剂疗效的潜力。然而，拓扑替康及其衍生物（包括SN-38）因其TOP1抑制活性而具有高度细胞毒性。在本研究中，我们合成了SN-38偶联的泊马度胺 (SN38-PROTAC)，并证明SN38-PROTAC能诱导泛素介导的RPL15降解，但对TOP1无此作用。SN38-PROTAC处理能诱导癌细胞分泌DAMPs，进而激活树突状细胞中的cGAS-STING信号通路。SN38-PROTAC对MCF7细胞的细胞毒性比SN-38低100倍。在一个小鼠模型中，SN38-PROTAC治疗提高了肿瘤内的细胞毒性T淋巴细胞/调节性T细胞 (CTL/Treg) 的比率，并使B16-F10肿瘤对PD-1抗体治疗敏感。在STING基因缺陷的小鼠中，SN38-PROTAC与PD-1抗体联合治疗的增强抗肿瘤效果消失了。我们的研究结果表明，通过诱导RPL15降解的SN38-PROTAC，有潜力以较低的细胞毒性增强免疫检查点抑制剂 (ICI) 在PD-1耐药癌症中的疗效。

### 第二部分 AI 大师评价

本研究旨在开发一种新型低毒性药物，以增强抗PD-1免疫疗法对黑色素瘤的疗效。研究人员创新性地设计并合成了一种靶向降解核糖体蛋白RPL15的PROTAC分子（SN38-PROTAC），该分子成功解除了母体化合物SN-38的TOP1抑制毒性，同时保留了诱导免疫原性细胞死亡的能力。关键发现表明，SN38-PROTAC能通过激活cGAS-STING通路，协同PD-1抗体显著抑制肿瘤生长。这项研究为开发低毒性的免疫检查点抑制剂增敏剂提供了全新策略，具有重要的临床转化潜力。

---

## 41. 多重基因编辑策略构建靶向EGFR的异基因CAR T细胞以增强对实体瘤的疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276526](https://pubmed.ncbi.nlm.nih.gov/41276526)
**期刊：** Nature communications
**PMID：** 41276526
**DOI：** 10.1038/s41467-025-66737-1

### 第一部分 原文与翻译

**英文原标题：** Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors.

**英文摘要原文：**
Chimeric Antigen Receptor (CAR) T cells have induced remarkable clinical responses in patients with hematological cancers. However, CAR T-cell therapies against solid tumors have not elicited similar outcomes since immunosuppressive barriers in the tumor microenvironment attenuate anti-tumor activity. Here, we describe a multifaceted approach to engineer allogeneic CAR T-cells resistant to both biochemical (hypoxia-adenosinergic) and immunological (PD-L1 and TGF-β) inhibitory signaling using an adenine base editor and a CRISPR-Cas12b nuclease. The resulting EGFR-targeting CAR T-cell product comprised a combination of six gene edits designed to evade allorejection (B2M, CIITA), prevent graft-versus-host disease (CD3E) and overcome biochemical (ADORA2A) and immunological (PDCD1, TGFBR2) barriers in solid tumor microenvironment of subcutaneously grown EGFR human lung tumor xenografts. This combinatorial genetic disruption enhances CAR T cell effector function and anti-tumor efficacy leading to improved tumor elimination and survival in xenograft and humanized mouse solid tumor models. Our strategy confers CAR T cells resistance to multiple clinically relevant inhibitory signaling pathways that are amplified in hypoxic tumor areas and may improve the therapeutic potential of CAR T-cells against solid tumors.

**中文摘要译文：**
嵌合抗原受体（CAR）T细胞在血液系统恶性肿瘤患者中已展现出卓越的临床疗效。然而，针对实体瘤的CAR T细胞疗法尚未取得类似成果，因为肿瘤微环境中的免疫抑制屏障削弱了其抗肿瘤活性。在本研究中，我们描述了一种利用腺嘌呤碱基编辑器和CRISPR-Cas12b核酸酶构建异基因CAR T细胞的多方面策略，使其能够抵抗生化（缺氧-腺苷能）和免疫（PD-L1和TGF-β）双重抑制性信号。由此产生的靶向EGFR的CAR T细胞产品包含六种基因编辑的组合，旨在规避同种异体排斥（B2M, CIITA）、预防移植物抗宿主病（CD3E），并克服皮下生长的人肺癌EGFR异种移植瘤的实体瘤微环境中的生化（ADORA2A）和免疫（PDCD1, TGFBR2）障碍。这种组合式基因敲除增强了CAR T细胞的效应器功能和抗肿瘤效力，从而在异种移植瘤和人源化小鼠实体瘤模型中改善了肿瘤清除效果并提高了存活率。我们的策略赋予了CAR T细胞对多种在缺氧肿瘤区域被放大的临床相关抑制性信号通路的抵抗能力，这可能提升CAR T细胞治疗实体瘤的潜力。

### 第二部分 AI 大师评价

本研究旨在解决异基因CAR T细胞疗法在实体瘤治疗中的核心挑战——肿瘤微环境的免疫抑制。研究团队创新性地采用腺嘌呤碱基编辑器与CRISPR-Cas12b技术，实现了对CAR T细胞进行六重基因编辑，使其能同时抵抗缺氧、PD-L1及TGF-β等多重抑制信号，并规避移植物抗宿主病与宿主排斥。这项研究不仅在临床前模型中证实了该策略能显著增强CAR T细胞的抗肿瘤活性与持久性，也为开发更有效、可“现货”供应的实体瘤细胞疗法提供了极具前景的新蓝图。

---

## 42. 自动化MRI系统在临床显著性前列腺癌检测中的开发、验证与真实世界应用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276524](https://pubmed.ncbi.nlm.nih.gov/41276524)
**期刊：** Nature communications
**PMID：** 41276524
**DOI：** 10.1038/s41467-025-66593-z

### 第一部分 原文与翻译

**英文原标题：** Automated MRI system for clinically significant prostate cancer detection development validation and real-world implementation.

**英文摘要原文：**
Prostate MRI enables detection of clinically significant prostate cancer (csPCa), yet variability in PI-RADS scoring limits reproducibility and throughput. Here, we report the development and validation of an automated MRI-based decision aid (ProAI) that estimates patient-level risk of csPCa from biparametric MRI and supports routine reporting. Training, internal validation, and external testing spanned 7849 examinations across six centres and two public datasets. On pooled external tests, the system achieved a patient-level AUC of 0.93 (95% CI, 0.91-0.95), comparable to PI-RADS while improving inter-case consistency. In a multi-reader, multi-case study involving nine clinicians, assistance increased accuracy from 0.80 to 0.86 and reduced reading time. Prospective implementation in 1978 consecutive examinations-maintained performance (AUC 0.92) and was associated with a 32% reduction in radiology workload. Performance generalised to the TCIA cohort (AUC 0.83). These findings indicate that an automated MRI-based decision aid can standardise reporting and enhance efficiency across prostate cancer care pathways. This study was registered at ClinicalTrials. Trial number: ChiCTR2400092863.

**中文摘要译文：**
前列腺MRI能够检测出临床显著性前列腺癌（csPCa），但PI-RADS评分的差异性限制了其可重复性和通量。在此，我们报告了一种基于自动化MRI的决策辅助系统（ProAI）的开发与验证，该系统可根据双参数MRI评估患者层面的csPCa风险，并支持常规报告流程。其训练、内部验证和外部测试共涵盖了来自六个中心和两个公共数据集的7849例检查。在汇总的外部测试中，该系统在患者层面实现了0.93的AUC（95% CI, 0.91-0.95），与PI-RADS评分相当，同时改善了病例间的一致性。在一项涉及九名临床医生的多阅片者、多病例研究中，该系统的辅助将诊断准确率从0.80提高到0.86，并减少了阅片时间。在前瞻性应用于1978例连续检查的实践中，该系统保持了优异的性能（AUC 0.92），并使放射科工作量减少了32%。其性能在TCIA队列中也得到了验证（AUC 0.83）。这些发现表明，基于自动化MRI的决策辅助系统能够规范报告流程，并提高整个前列腺癌诊疗路径的效率。本研究已在ClinicalTrials注册。试验编号：ChiCTR2400092863。

### 第二部分 AI 大师评价

本研究旨在开发并验证一个名为ProAI的自动化MRI决策辅助系统，以提高临床显著性前列腺癌（csPCa）的检测效率和准确性。通过在多中心、大规模数据集上进行严格的训练与验证，并进行真实世界的前瞻性应用，研究证实了该系统的卓越性能。其关键发现是，ProAI不仅在诊断准确性上媲美传统的PI-RADS评分，还显著提升了报告的一致性、缩短了阅片时间，并大幅减轻了放射科的工作负荷。这项工作的突出价值在于成功将AI工具从理论验证推向临床实践，展示了其优化诊疗流程、实现标准化诊断并提升医疗服务效率的巨大潜力。

---

## 43. 真实世界中，慢性髓系白血病治疗指南依从性差与生存率下降相关

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276519](https://pubmed.ncbi.nlm.nih.gov/41276519)
**期刊：** Blood cancer journal
**PMID：** 41276519
**DOI：** 10.1038/s41408-025-01423-5

### 第一部分 原文与翻译

**英文原标题：** Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究基于真实世界数据，旨在探讨慢性髓系白血病（CML）患者治疗过程中，临床指南依从性对生存结局的实际影响。研究核心发现指出，在真实临床环境中，对治疗指南的依从性不佳与患者生存率的显著下降直接相关。这项研究的价值在于，它强调了将临床试验结果转化为实际临床效益的重要性，并为临床医生和卫生政策制定者提供了有力证据，凸显了提高CML管理中指南依从性的紧迫性和必要性。由于摘要缺失，研究的具体方法和数据细节有待全文揭示。

---

## 44. 丹麦乳腺癌与收入损失：异质性结局与纵向效应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276509](https://pubmed.ncbi.nlm.nih.gov/41276509)
**期刊：** Nature communications
**PMID：** 41276509
**DOI：** 10.1038/s41467-025-66524-y

### 第一部分 原文与翻译

**英文原标题：** Breast cancer and income loss in Denmark: heterogeneous outcomes and longitudinal effects.

**英文摘要原文：**
Income loss after breast cancer is an important area of research, but long-term impacts and heterogeneous effects are understudied. Here, we measure the effect of breast cancer on personal and household equivalized income of females in Denmark from 2000-2018 using Danish register data. We perform a cohort study and match on age, income, employment, comorbidities, healthcare utilization, and other socioeconomic and demographic variables at cohort entry, to investigate impacts across subpopulations over 10 years. We also perform an event study difference-in-difference analysis over the same period. Our study finds personal income loss averaging €7138 over 10 years in the non-retired population. The working population, students, and those in worse health suffer disproportionate loss. Household income losses are smaller and recover within 10 years. Overall, the Danish economic protections are effective in mitigating long-term economic impact of breast cancer, though there is room for improvement in protection of the most vulnerable.

**中文摘要译文：**
乳腺癌后的收入损失是一个重要的研究领域，但其长期影响和异质性效应尚未得到充分研究。本研究利用丹麦的登记数据，衡量了2000年至2018年间乳腺癌对丹麦女性个人及家庭等效收入的影响。我们进行了一项队列研究，在队列入组时对年龄、收入、就业状况、合并症、医疗保健利用情况以及其他社会经济和人口统计学变量进行匹配，以探究其在10年间对不同亚人群的影响。同期，我们还进行了一项事件研究双重差分分析。我们的研究发现，在非退休人群中，10年内的个人平均收入损失为7138欧元。在职人群、学生以及健康状况较差者遭受了更严重的损失。家庭收入损失较小，并在10年内恢复。总体而言，丹麦的经济保障措施在缓解乳腺癌的长期经济影响方面是有效的，但在保护最脆弱群体方面仍有改进空间。

### 第二部分 AI 大师评价

本研究基于丹麦全国性登记数据，采用稳健的队列研究和双重差分法，精细刻画了乳腺癌对女性长达十年的个人及家庭收入的异质性影响。其核心发现揭示了即便在福利体系完善的国家，特定弱势群体（如在职者、学生、健康状况不佳者）依然面临显著的个人收入损失，而家庭收入则展现出更强的恢复力。该研究的创新价值在于其大规模的纵向设计和对亚群差异的深入分析，为优化癌症患者的社会经济支持政策、实现更精准的保障提供了高质量的循证依据，具有重要的公共卫生和政策参考价值。

---

## 45. 靶向成纤维细胞来源的血小板反应蛋白2可破坏结直肠癌肿瘤前沿的免疫排斥微环境

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276505](https://pubmed.ncbi.nlm.nih.gov/41276505)
**期刊：** Nature communications
**PMID：** 41276505
**DOI：** 10.1038/s41467-025-66485-2

### 第一部分 原文与翻译

**英文原标题：** Targeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer.

**英文摘要原文：**
Fibrotic colorectal cancers (CRC) are largely microsatellite-stable and display desmoplastic stroma with poor immune infiltration. Here we identify thrombospondin-2 (THBS2) as a key regulator of the immune-exclusionary phenotype in fibrotic CRC. THBS2 is highly expressed by matrix cancer-associated fibroblasts at the tumor front. In an orthotopic model using desmoplastic tumor organoids, global or fibroblast-specific Thbs2 deletion disrupts the exclusionary barrier and increases intratumoral CD8 T cells. Mechanistically, THBS2 limits recruitment of CXCR3 CD8 T cells by restraining dendritic- and macrophage-derived CXCL9/10. Depletion of these myeloid cells or blockade of CXCL9/10-CXCR3 signaling abolishes the enhanced CD8 T-cell influx and antitumor efficacy. Spatial profiling demonstrates that THBS2 loss induces proximity between CD8 T cells and myeloid cells and upregulates chemokines. Despite increased infiltration, CD8 T cells manifest exhaustion, rendering tumors highly susceptible to immune checkpoint blockade. THBS2 thus represents a tractable CAF-restricted target to overcome immune exclusion in fibrotic CRCs.

**中文摘要译文：**
纤维化结直肠癌（CRC）大多是微卫星稳定的，并表现为伴有不良免疫浸润的促纤维增生性基质。本研究将血小板反应蛋白-2（THBS2）鉴定为纤维化CRC中免疫排斥表型的关键调控因子。THBS2在肿瘤前沿的基质型癌症相关成纤维细胞中高表达。在使用促纤维增生性肿瘤类器官的原位模型中，全局性或成纤维细胞特异性的Thbs2基因敲除破坏了排斥屏障，并增加了肿瘤内CD8 T细胞的数量。从机制上看，THBS2通过抑制树突状细胞和巨噬细胞来源的CXCL9/10，来限制CXCR3阳性CD8 T细胞的招募。清除这些髓系细胞或阻断CXCL9/10-CXCR3信号通路，会消除增强的CD8 T细胞流入和抗肿瘤效力。空间分析表明，THBS2的缺失诱导了CD8 T细胞与髓系细胞的接近，并上调了趋化因子。尽管浸润增加，CD8 T细胞表现出耗竭状态，这使得肿瘤对免疫检查点阻断高度敏感。因此，THBS2代表了一个可行的、仅限于癌症相关成纤维细胞（CAF）的靶点，用以克服纤维化CRC中的免疫排斥。

### 第二部分 AI 大师评价

本研究旨在揭示纤维化结直肠癌（CRC）中免疫排斥微环境的关键调控机制。研究团队通过原位类器官模型和空间分析技术，发现癌症相关成纤维细胞（CAF）分泌的血小板反应蛋白-2（THBS2）通过抑制髓系细胞产生趋化因子CXCL9/10，从而阻碍CD8 T细胞浸润，形成免疫排斥屏障。该研究的创新之处在于精准定位了THBS2作为关键“守门人”的角色，并证实靶向THBS2能有效“打开”肿瘤微环境，增强免疫检查点抑制剂的疗效，为治疗这类“冷”肿瘤提供了极具潜力的CAF特异性新靶点。

---

## 46. 结合多基因风险与低密度脂蛋白（LDL）、C反应蛋白（CRP）及脂蛋白(a)（Lp(a)）预测冠状动脉疾病：一项基于英国生物样本库（UK Biobank）的研究。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41123520](https://pubmed.ncbi.nlm.nih.gov/41123520)
**期刊：** Journal of the American College of Cardiology
**PMID：** 41123520
**DOI：** 10.1016/j.jacc.2025.08.069

### 第一部分 原文与翻译

**英文原标题：** Combining Polygenic Risk With LDL, CRP, and Lp(a) to Predict Coronary Artery Disease: UK Biobank Study.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究旨在探讨将多基因风险评分（PRS）与传统的生物标志物——低密度脂蛋白（LDL）、C反应蛋白（CRP）和脂蛋白(a)（Lp(a)）相结合，是否能更准确地预测冠状动脉疾病的发生风险。研究基于大规模的英国生物样本库（UK Biobank）数据，提示其方法具有较高的统计学效力。其创新性在于整合了遗传易感性与临床常规指标，有望为冠心病的风险分层和个体化预防提供更精准的模型。尽管缺乏摘要信息，但该标题预示着一项对于心血管疾病预防具有重要临床转化潜力的研究。

---

速递结束，祝您工作愉快！